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Abstract

Cardiac Arrest and Global Ischemia Reperfusion Injury: Role of mitochondria and Cannabinoid
Receptor 2 signaling.

By Jennifer Leigh Bradley

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2021

Director: Wanchun Tang, MD, MCCM, FAHA, FNAI
Affiliate Professor, Department of Microbiology and Immunology
Professor, Emergency Medicine

Sudden cardiac arrest is a major public health challenge in the United States with very
poor outcomes. Current advanced cardiac life support therapies with cardiopulmonary
resuscitation, defibrillation, and medications save less than 5% of victims despite substantial
evidence that many of these lives could be saved with improved resuscitation protocols including
the expanded use of hypothermia. Clinically, no effective treatment other than targeted
temperature management is utilized. We have previously demonstrated that WIN55, 212-2
(WIN55), a non-selective cannabinoid CB1/CB2 receptor agonist, induced hypothermia when
administered immediately following resuscitation with significantly improved post-resuscitation
myocardial and cerebral function and duration of survival. We further demonstrated that the
hypothermia effect of WIN55 is mediated through CB1 receptors.
However, the results of our previous studies indicated that the beneficial effect of WIN55
on myocardial and cerebral function and duration of survival may not be solely due to its

hypothermic effect. The overall objective of this study is to determine if cardiac arrest causes
mitochondrial dysfunction and increased plasma concentrations of TNFα, IL6 and IL10.
Intramuscular Administration of SR141716A (CB1 antagonist) before ventricular fibrillation +
cardiopulmonary resuscitation followed by infusion of WIN55 5 min after return of spontaneous
circulation will prohibit the release of inflammatory mediators caused by cardiac arrest via the
CB2 receptor.
We explored the effects of cardiac arrest on mitochondria populations and heart whole
tissue lysate proteomics utilizing the Weil Institute’s in vivo rat model of cardiac arrest and
cardiopulmonary resuscitation. We have discovered that brain mitochondria are more sensitive to
global ischemia compared to heart mitochondria. Additionally, complex I is the most sensitive
electron transport chain complex to ischemic injury and is a major control point of the rate of
oxidative phosphorylation following cardiac arrest and cardiopulmonary resuscitation.
Preservation of brain mitochondrial activity and function during cardiac arrest may enhance
outcomes and recovery.
A recent article focusing on acute myocardial infarction was able to link S100A8 and
S100A9 gene upregulation during ischemia and reperfusion and revealed this caused
mitochondrial dysfunction in cardiomyocytes. S100A8 and S100A9 protein expression levels
were upregulated in rat LV Apex epicardium whole tissue lysate from animals that experienced
global ischemia reperfusion injury via cardiac arrest and cardiopulmonary resuscitation. Further
studies are necessary to confirm S100A8 and S100A9 proteins increase expression in brain and
heart tissue samples after cardiac arrest and cardiopulmonary resuscitation.
Testing WIN55 as a possible pharmacologic tool, in vitro results indicated that WIN55
was anti-inflammatory. Therefore, we moved to in vivo studies with intramuscular administration

of SR141716A (CB1 antagonist) before ventricular fibrillation + cardiopulmonary resuscitation
followed by infusion of WIN55 5 min after return of spontaneous circulation. After treatment,
plasma concentrations of TNFα, IL6 and IL10 were decreased at return of spontaneous
circulation 4hrs. One possible mechanism to drive down proinflammatory cytokine release is
binding CB2. WIN55 could be a novel pharmacologic tool against cardiac arrest as it can induce
hypothermia and it has ant-inflammatory effects. Further studies are needed to determine
mechanism of action for anti-inflammatory effects as peroxisome proliferator-activated receptors
are also cannabinoid targets.

CHAPTER 1: Introduction and Literature Review
I.

Cardiac Arrest
A. Epidemiology and Disease Spectrum
Cardiac arrest (CA) is a major public health problem with substantial morbidity and

mortality. It is the cessation of cardiac mechanical activity, as confirmed by the absence of signs
of circulation (1). CA is characterized by severe and generalized ischemia that persists during the
resuscitation efforts and reverses only after restoration of spontaneous circulation (ROSC) (2).
An operational definition of sudden cardiac arrest (SCA) is unexpected CA that results in
attempts to restore circulation (1). If resuscitation attempts are unsuccessful, this situation is
referred to as sudden cardiac death (SCD). In the United States, any-mention sudden cardiac
death (SCD) mortality in 2017 was 379, 133 (1). Over the past 5 decades, the strategy of
cardiopulmonary resuscitation (CPR) has been focused on early defibrillation, better and more
effective chest compression, and more recently, post-resuscitation management including
therapeutic hypothermia. However, the current outcomes of CPR are disappointing, which yield
a functional survival rate of only 8.2% (1). Circulatory failure and myocardial dysfunction
resulting from CA largely contribute to morbidity and mortality after initially successful CPR
(3). Out-of-hospital cardiac arrest (OHCA) is a significant cause of death and disability in adults
with 356,461 reported “EMS-worked” cases per year in the United States (1).
B. Ischemia Reperfusion Injury
Ischemia is an imbalance between the oxygen demand of the tissue and the oxygen
delivery that it receives. Oxygen delivery could be simple diffusion or the heart delivering
oxygen conductively (oxygen through blood flow). Whenever oxygen delivery does not match
demand, technically it is ischemia. Ischemia is a condition where energy expenditure outpaces
energy production. For aerobic cells ischemia is a critical change in the oxygen demand to
delivery ratio (4). Ischemia Reperfusion (IR) injury is a complex process, which involves several
17

interrelated factors, including a decrease in cellular adenosine triphosphate (ATP) levels,
accumulation of hydrogen ions, calcium overload, and production of reactive oxygen species
(ROS) (5). Cerebral and myocardial tissue suffers from IR injury even after successful CPR (6,
7). The destructive effects of IR arise from the acute generation of ROS subsequent to
reoxygenation, which inflicts direct tissue damage and initiates a chain of deleterious cellular
responses leading to inflammation, cell death, and eventually organ failure (8). The cessation
(ischemia) and restoration (reperfusion) of cerebral blood flow (CBF) after CA induce
inflammatory processes that can result in additional brain injury (9). Post-cardiac arrest (postCA) ischemia induces neurodegeneration, cerebral edema and impaired cerebrovascular
autoregulation within the brain (10). This phenomenon is reflected in 2004 epidemiological data
that shows brain injury as the leading cause of death post-CA, accounting for 68% and 23% of
OHCA and in-hospital cardiac arrest (IHCA) deaths (10).
Post-arrest myocardial dysfunction includes the development of low cardiac output (CO)
or ventricular systolic or diastolic dysfunction (7). The pathophysiology involves cardiovascular
IR injury and cardiovascular toxicity from excessive levels of inflammatory cytokine activation,
among other contributing factors (7). There is an almost instant inflammatory response where
interleukins are produced by affected tissues and the endothelial cells of the local capillary
vasculature (11). Chemical signaling results in white blood cells being attracted to affected areas
and attaching themselves to the endothelial lining of the capillaries, resulting in capillary
blockage and further ischemia (11). It is recognized that cells can be programmed to die by
cellular signaling mechanisms via the processes of apoptosis and autophagy.
C. Mitochondrial Dysfunction
Neurologic and myocardial dysfunction after successful resuscitation is prominent and
mitochondrial dysfunction is a key determinant of poor outcomes (9, 12-16). Neurons and
18

cardiomyocytes, two high energy-consuming organs, are enriched with mitochondria and are
highly sensitive to IR injury (17). The central nervous system receives almost a third of the CO
(9). Morbidity and mortality after initially successful CPR can be attributed to immediate and
delayed effects of reperfusion in the central nervous and cardiovascular systems (18). The
principal role of mitochondria is to generate cellular energy (ATP) by the mitochondrial electron
transport chain (ETC) through oxidative phosphorylation (OXPHOS). An adequate amount of
energy by mitochondria is crucial for neuronal excitability and survival. In addition,
mitochondria are critically involved in the regulation of cell death via apoptosis, autophagy and
necroptosis (14, 19).
Mitochondrial dysfunction is one hallmark of IR injury, which induces neuronal death (9,
20). During the ischemic phase, OXPHOS is inhibited by lacking oxygen, causing low levels of
adenosine triphosphate (ATP) and cellular acidification secondary to the diverging of glycolytic
pyruvate to lactate (21). Upon reperfusion, the rapid re-establishment of OXPHOS induces
several mitochondrial events such as ROS generation, H+ leaking, mitochondrial Ca2+ overload
and the release of cell-death inducing protein cytochrome c (21).
Ultrastructural and functional injury occurs early in and progresses during ischemia (22).
Mitochondrial morphological dynamics are relevant to IR injury (23, 24). Under physiological
conditions, the removal of damaged or dysfunctional mitochondria is mediated by mitophagy, a
mitochondrial-selective subtype of autophagy that involves sequestration and subsequent fusion
of mitochondrial contents with lysosomes containing degradative enzymes (25, 26). This process
allows maintenance of mitochondrial homeostasis; however, in the context of major cellular
stress like that of IR or heart failure, mitochondrial DNA leak out from damaged and necrotic
cardiomyocytes into the cytoplasm and extracellular space (26, 27). Mitochondrial DNA serves
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as the damage-associated molecular patterns (DAMPs) that can activate several proinflammatory pathways, such as toll-like receptor (TLR) on immune cells such as circulating
neutrophils and macrophages, leading to the formation of inflammatory cytokines TNFα and IL6
(Figure 1) (28-30). Mitochondrial DNA has also been shown to activate inflammasome
complexes, which are responsible for recruiting active caspase-1 and converting pro-IL1β and
proIL18 into their bioactive forms IL1β and IL18 (25, 31). Mitochondrial damage from
cardiovascular events like IR thus appear to have major downstream effects on the development
of inflammation, which may, in turn, influence the severity of the ischemic insult.
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Figure 1. Role of TLR in production of inflammatory mediators. Adapted from (29).
An experiment with a mitochondrial protective agent (SS31) demonstrates improved
cardiac contractility and ejection fraction (EF) with lower levels of inflammatory cytokines
TNFα and IL1β (32). Translational studies have yielded similar results. Levels of circulating
cell-free mitochondrial DNA were found to be a more accurate prognostic marker in CA patients
(33). Additionally, in the COMICA study, higher serum levels of mitochondrial injury marker,
cytochrome c, were seen in post-CA patients compared to controls. Even higher levels were seen
in non-survivors versus survivors (34). Neurological outcomes in post-CA have not been as
extensively studied. However, anti-inflammatory studies in a rat model of cerebral IR yielded
comparable results with reduced cerebral infarct sizes, improved neurobehavioral scores and
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lower levels of oxidative stress following treatment (35). Based on these findings, further
research into agents that can attenuate the pro-inflammatory pathway in mitochondrial
dysfunction could prove to be crucial in improving functional and mortality outcomes associated
with IR.
Recognition of potential mitochondrial-driven pathology in IR has led to growing interest
in investigating the relationship between mitochondrial injury and functional outcomes following
SCA and IR. An imbalance in mitochondrial dynamics contributes to brain injury after cardiac
arrest. Thus, targeting mitochondria is a promising neuroprotective strategy (36). Activation of
the mitochondrial permeability transition represents a major mechanism of IR injury. A CB2
receptor agonist (JWH133) protected mitochondria against IR injury and reduced apoptosis
through inhibition of apoptotic protein released from the mitochondrial permeability transition
pore (MPTP) (37). Administration of the cannabinoid agonist WIN 55,212-2 after hypoxia
ischemia in fetal lambs reduces brain injury, diminishing both apoptosis and mitochondrial
dysfunction (38).
D. Post Cardiac Arrest Syndrome
Whole-body ischemia and reperfusion due to CA and subsequent ROSC constitute post-CA
syndrome (PCAS) (39). PCAS is a combination of post-cardiac brain injury, circulatory
dysfunction, systemic IR response and persistent precipitating pathology proposed by Nolan et
al. in 2008 (40-42). Binks et al. state PCAS can be divided into four phases 1) immediate postarrest (occurs in the first 20 minutes following ROSC 2) early post-arrest (occurs between 20
minutes and 6 to 12 hours after ROSC) 3) intermediate (between 6 to 12 hours and 72 hours) 4)
recovery (extends from 3 days and beyond) (43). Management of PCAS patients includes
complex and multidisciplinary interventions. Early and intensive management should be focused
on hemodynamic stability and neurologic recovery (42).
22

PCAS is most notably characterized by profound IR injury. Due to CA being an extreme of
shock states, oxygen delivery is dramatically reduced during an arrest event, leading to profound
tissue hypoxia (44). Depending on the cause of the arrest and severity of PCAS, many patients
will require multiple organ support (45). Treatment received during this post-resuscitation period
influences the overall outcome significantly, particularly quality of neurological recovery (45).
Although CA impacts all organ systems, its impact is most profound on the neurological system
as brain tissue is exquisitely sensitive to lack of oxygen (46). Post-CA anoxic brain injury is a
major cause of morbidity and mortality, and is responsible for two thirds of intensive care unit
(ICU) deaths in the post-CA period (47). Post–CA myocardial dysfunction also contributes to a
low survival rate after in- and out-of-hospital CA. However, preclinical and clinical evidence
indicates that this phenomenon is both responsive to therapy and potentially reversible (10).
Successful resuscitation from CA is usually characterized by the development of an IR
syndrome of the body that may enhance cerebral and cardiac damage (41). The main determinant
of this syndrome is a generalized activation of inflammatory reactions resulting in symptoms
similar in many aspects to those of sepsis (48). Inflammatory responses play pivotal roles in the
pathophysiology of cerebral and cardiac damage after CA/CPR (48-51). Systemic inflammation
promotes disorders in the macro-circulation and micro-circulation and increases vascular
permeability promoting protein extravasation and edema formation in the tissues, due to
metabolic imbalance, leucocyte activation, endothelial toxicity and impairment of mitochondrial
respiratory chain activity (40, 52).
Management of the post–CA patient is complex, and addresses multiple key issues
simultaneously: diagnosing and treating the etiology, minimizing hypoxic brain injury,
addressing sequelae of global IR injury, and managing cardiovascular dysfunction (53). Global
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cerebral ischemia induced by CA and followed by reperfusion triggers a multitude of processes
that ultimately result in neuroinflammatory responses with activation of glial cells, release of
proinflammatory cytokines, and delayed neuronal death (54). Levels of TNFα and IL6 were
shown to be strongly associated with the severity of PCAS, mortality rate, and neurologic
outcomes (54). The severity of this syndrome will vary with the duration and cause of CA (45).
II.

Role of Inflammatory Mediators in Cardiac Arrest
A. Pro-inflammatory mediators (Tumor Necrosis Factor α and interleukin 6)
Inflammatory responses play a pivotal role in the pathophysiology of brain and heart

damage after CA/CPR, which leads to neuronal death, myocardial dysfunction, and apoptosis
(55-57). Systemic and central nervous system (CNS) levels of various cytokines including tumor
necrosis factor (TNF)α, interleukin (IL)1, IL6, IL8, IL10, and others are increased after CA (50,
51). One definitive mechanism of cerebral IR injury is inflammation. It is characterized by the
activation of glial cells, influx of peripheral immune and inflammatory cells, high concentrations
of ROS and release of pro-inflammatory mediators, including cytokines and adhesion molecules
(58). The most studied cellular sources of ROS within the heart include cardiomyocytes,
endothelial cells, and neutrophils (59). One function of cytokines is to change the physiological
state of cells and the way they respond to environmental stimuli (60). TNFα induces
inflammation, activates vascular endothelium, orchestrates the tissue recruitment of immune
cells and promotes tissue destruction (60). Inflammation is a protective response of the host to
infections and tissue damage, characterized by a series of reactions, including vasodilation and
recruitment of immune cells and plasma proteins to the site of infection or tissue injury (61).
Normally, inflammation is beneficial to the host and can be resolved in a timely manner;
however, deregulated inflammatory responses can cause excessive or long-lasting tissue damage,
contributing to the development of acute or chronic inflammatory diseases (61). Increased
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release of DAMP molecules and cellular dysfunction in activated microglia and astrocytes
contribute to ischemia-induced cytotoxic and pro-inflammatory cytokine generation, and
ultimately to delayed death of neurons (58). TNFα has been shown to play an important role in
the pathogenesis of neurological diseases (62). It has been demonstrated that the brain and innate
immune system are engaged in bidirectional cross-talk. The cerebral inflammatory cascade
comprises an increase of neutrophil recruitment and peripheral macrophage infiltration,
activation and migration of microglia, also known as brain macrophages and release of proinflammatory stimuli within the brain. When an ischemic event occurs, the normally immuneprivileged brain environment collapses, DAMP molecules released by cellular injury can be
recognized as invader to induce the activation of toll like receptors and triggers the activation
process of nuclear factor ƙB (NFƙB), which is linked to the transcription of numerous
proinflammatory genes (58).
In the central nervous system, TNF is produced primarily by microglia and astrocytes in
response to a wide range of pathological processes, including infection, inflammatory disease,
ischemia and traumatic injury (63).This leads to neurologic damage. Cerebral injury is correlated
to the abundant synthesis of inflammatory cytokines during CA and RES. In the brain, cytokines
are not only produced by the cells of the immune system, but are also expressed in resident brain
cells including neurons and glia. Neuroinflammation can continue for days and months, which
contributes to neurological damage that ultimately determines the impaired recovery following
CA/CPR (58). Increasing evidence reveals that suppressing the inflammatory process facilitates
neuroprotection and has the potential for use in the clinical treatment of cerebral IR damage
regarding CA (58).
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Post-resuscitation myocardial dysfunction has been ascribed to post-ischemic stunning,
the pathobiology of which has been well described in models of global and regional myocardial
ischemia and reperfusion (64). Tumor necrosis factor (TNF) has been implicated in the
pathogenesis of a number of cardiovascular diseases, including atherosclerosis, myocardial
infarction, heart failure, myocarditis and cardiac allograft rejection, and vascular endothelial cell
responses to TNF may underlie vascular pathology in many of these conditions (63). TNFα
increases during the early post-resuscitation period and may play a role in post-resuscitation
myocardial dysfunction (64). Niemann et al. show the time courses of LV systolic and diastolic
dP/dt and TNFα are significantly negatively correlated. TNFα concentration is a statistically
significant predictor of systolic dP/dt, with higher TNF concentrations being associated with
decreased left ventricular systolic function (64). Hemodynamic effects of TNFα are
characterized by decreased contractility, reduced EF, decreased systemic vascular resistance,
hypotension, and biventricular dilation. TNFα is believed to exert its myocardial depressant
effect by disrupting calcium homeostasis or calcium sensitivity and the normal myocardial
contraction relaxation cycle (64).
Cardiotoxicity is primarily attributed to TNF-induced cardiomyocyte apoptosis (60).The
inflammatory response after ROSC is characterized by polymorphonuclear leukocyte activation,
adhesion molecule expression, reactive oxygen species (ROS) production from inducible nitric
oxide synthase (iNOS), and release of cytokines such as TNFα and interleukin 6 (IL6) (7). IL6
represents a keystone cytokine in infection, cancer and inflammation, in which it drives disease
progression or supports the maintenance of immunological reactions (65). An enormous
repertoire of biological functions can be attributed to the cytokine IL6, establishing IL6 as a
pleiotropic cytokine and a major player in health and disease (66). Soluble ambient IL6 is
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available during massive inflammation (66). Baseline IL6 was a good predictor of in-hospital
mortality and poor functional outcome. It was associated with mortality in multivariable analysis
(51). IL6 has context-dependent pro- and anti-inflammatory properties and is regarded as a
prominent target for clinical intervention (65).
Cytokine production is also altered by stress. Increased production of TNFα, IL6 and
IL1β contributes to the acute-phase reaction and hypermetabolic response that accompanies
overwhelming infection , hemorrhage, injury and surgery (64). These stress-activated cytokines
all have the potential to produce cardiac decompensation when in sufficiently high
concentrations (64). The effects of stress-activated cytokines extend beyond the myocardium.
B. S100A8 and S100A9
S100A8 and S100A9, also known as myeloid-related protein 8 (MRP8) and MRP14
respectively, are DAMPs that belong to the S100 family. Both are constitutively expressed in
neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated
upon the onset of trauma, infection, stress and other inflammatory processes (67-70). Under
physiological conditions they can exist as homodimers, but under inflammatory states they
preferentially form heterodimers with each other (S100A8/A9) because the heterodimeric
structure confers increased resistance to the protease-rich environment of inflammation (71).
Additionally, S100A8 and S100A9 contain a characteristic helix-loop-helix motif with charged
amino acid residues, giving them a high affinity for divalent ions such as calcium (69).
Therefore, they are calcium-binding proteins that have been implicated as key modulators
in the development of inflammation (67). Together, these features allow S100A8 and S100A9 to
achieve functional diversity both intracellularly and extracellularly (69). They are able to exhibit
both intracellular and extracellular effects on various cells of the innate immune system and have
therefore become a point of interest for therapeutic intervention (Figure 2) (67, 70).
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Figure 2. Involvement of S100 proteins in stress and inflammation. Adapted from (70)
Intracellular S100A8/A9 is best known for the ability to regulate trans endothelial
migration of leukocytes (72). Transmigration is primarily achieved through extensive remodeling
of the cytoskeletal structures which, in turn, is controlled by elevation of intracellular calcium
levels and specific protein phosphorylation (72). As S100A8 and S100A9 are the major calciumbinding proteins expressed in neutrophils and monocytes, it has been demonstrated that calcium28

induced S100A8/A9 complexes promote microtubule polymerization via direct interaction with
tubulin (72).
Extracellular S100A8 and S100A9 function primarily as DAMP molecules after being
released from damaged or activated cells. The exact secretion mechanism remains unknown;
however, it appears to require monocytic activation of both protein kinase C and the receptor for
advanced glycation end products (RAGE) pathways (73, 74). Once released, S100A8/A9 exerts
its effects through two different innate immune receptors: TLR4 and RAGE (67). Upon binding
to TLR4 on phagocytes, S100A8/A9 triggers the MyD88-dependent pathway, where MyD88
recruits and activates IL1R-associated kinases (IRAKs) and TNFR-associated factor 6 (TRAF6).
This, in turn, causes a downstream signaling cascade, ultimately leading to loss of inhibition of
transcription factors NF-kB and AP-1. These factors can then translocate the nucleus and induce
expression of pro-inflammatory cytokines such as TNFα, IL6 and IL8 (Figure 3) (69). Similarly,
binding to RAGE results in subsequent activation of JNK and JAK-STAT signaling (75). Effects
are under investigation but appear to inhibit anaerobic glycolysis in myocardium in the setting of
ischemia (76). Overall, S100A8/A9 serves as a key modulator in the early stages of inflammation
and can have a profound impact on long-term severity of inflammatory diseases.
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Figure 3. S100A8/A9 effects through TLR4 (77).
C. Anti-inflammatory mediators (interleukin 10)
Anti-inflammatory cytokines, such as IL10, have been shown to inhibit the LPS-induced
production of pro-inflammatory cytokines (78). IL10 is a secondary cytokine released by
leukocytes or endothelial cells following stimulation by IL1β and TNFα (51). IL6 might also
contribute to the regulation of inflammation by inducing IL10‑producing B regulatory (Breg)
cells (66). Zhang et al show an elevated level of IL-10 attenuates LPS-induced activation of NFκB, JNK, ERK and p38MAPK, which results in reduced production of TNFα and IL6 (78).
Understanding the role of IL10 in the regulation of metabolic processes is essential both for
deciphering how IL10 acts to control inflammatory responses and for discovering key molecular
controlling processes involved in the resolution of inflammation (79). IL10 production was first
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described in TH2 cells where its expression accompanies that of the TH2 type cytokines IL4, IL5
and IL13 (80).
In the absence of IL-10 signaling, macrophages accumulate damaged mitochondria in a
mouse model of colitis and inflammatory bowel disease, which results in dysregulated activation
of the NLRP3 inflammasome and production of IL-1β (79). The absence of IL10 leads to ROS
production from accumulated mitochondria (79). Various cell types can express IL-10, which
makes IL10 regulation challenging (80). IL10 might act to reverse the metabolic program
associated with inflammatory response (79).
III.

Cannabinoids
A. Endocannabinoid System (ECS)
The psychoactive properties of marijuana have been known for thousands of years,

however, the biological basis of the effects of marijuana and its bioactive ingredients,
collectively called cannabinoids, has unfolded in the last few decades (81, 82). Since 1998, the
use of cannabis for medical purposes has become legal in 29 states (according to state, but not
federal law) in the USA, and numerous countries have also opted to legalize marijuana for
medicinal use (83). Cannabinoid compounds are being extensively studied for therapeutic
potential. Although there is an abundance of information on the role of cannabinoids in the
central and peripheral nervous systems, their role in the cardiovascular system is more complex
(84). Cannabinoids and their synthetic and endogenous analogs are best known for prominent
psychoactive properties, however, their cardiovascular effects were recognized as early as the
1960’s (85). Cannabinoids are highly lipophilic molecules that have been shown to alter the
functional activities of immune cells in vitro and in vivo. The term “exogenous cannabinoid” has
been applied to cannabinoids that are extracted from the marijuana plant cannabis sativa or are
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synthesized in the laboratory (86). WIN55,212-2 (WIN55) is an exogenous cannabinoid (Figure
4).

Figure 4. WIN55 is a full agonist for CB1 and CB2 (87)
Cannabinoids modulate inflammation through multiple pathways (88). They have been
reported to have immunosuppressive activity and alter macrophage functions (89). It has been
reported that, under pathological conditions, cannabinoids can avoid mitochondrial dysfunction,
thus inhibiting apoptotic signaling (38) .Cannabinoids were shown in vivo and in vitro, to exert
their immunosuppressive properties through 4 main pathways: induction of apoptosis, inhibition
of cell proliferation, inhibition of cytokines, and chemokine production and induction of
regulatory T cells (tregs) (90). Distinct phytocannabinoids may activate immune cells by
receptor-mediated as well as by non-receptor mediated modes (91).Cannabidiol inhibits IL1,
IL12, TNF-α and interferon-gamma cytokine release by peripheral blood mononuclear cells, and
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enhances production of the Th2-associated cytokines, IL4 and IL10 (90). The ECS, which
comprises specific cannabinoid receptors, endogenous ligands (endocannabinoids), and synthetic
and degradative pathways, is a new therapeutic target in a variety of disorders, such as
inflammation and tissue injury, including the cardiovascular system (37).
B. Cannabinoid Receptors
Endocannabinoids (eCBs) act locally in a paracrine or autocrine manner by activating
cannabinoid receptors (83). The endocannabinoid signaling system has emerged as an important
target for therapeutic drug development, although the design of receptor-selective ligands has
remained a challenge (92). Endocannabinoids may limit hepatic injury by modulating the
expression of adhesion molecules and the infiltration and activation of inflammatory cells by
CB2 dependent mechanisms, which is consistent with the emerging role of CB2 receptors in
regulating microglial cell function and neuroinflammation (8). The discovery of cannabinoid
receptors that mediate the action of THC and synthetic cannabinoids, precipitated the search for
the endogenous ligands that bind these receptors. Arachidonoyl ethanolamide or anamide (AEA)
and 2-arachidonoylglycerol (2-AG) represent the primary endogenous ligands that bind and
activate CB1 and CB2 (91).
These cannabinoid receptors belong to the G-protein coupled receptor family and play a
key role in downstream intracellular regulation of apoptosis and inflammation (82). Both
receptors have seven transmembrane domains, are coupled to inhibitory G proteins, and are
linked to signaling cascades that may involve adenylyl cyclase and cAMP, mitogen-activated
protein (MAP) kinase, and the regulation of intracellular calcium (91). Cannabinoid receptors
signal via Gi/o-protein-dependent pathways to inhibit adenylyl cyclase and modulate ion-channel
function, but also activate mitogen-activated protein kinases (p44/42 MAPKs, p38, ERK, and
JNK) or ceramide signaling, and can also engage G-protein-independent pathways via β-arrestins
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(Figure 5) (83). Saroz et al. recently reported CB2 activation induces simultaneous Gαi and Gαs
(G protein-stimulating adenylate cyclase) coupling, which produces a delayed cAMP flux in
human primary leukocytes (93, 94). The cannabinoid system with its receptors (CB1 and CB2),
provides neuroprotection against cerebral and spinal cord ischemia-reperfusion (IR) injuries (95).
During ischemic injury, endocannabinoids accumulate, cannabinoid receptors are up-regulated,
and treatment with cannabinoid agonists (either endocannabinoids or
phytocannabinoids/synthetic cannabinoids) protects neurons against damage resulting from
ischemic stroke (96).
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Figure 5. Cannabinoid receptor signaling (a) The adenylate cyclase (AC) pathway. Gαi
signaling downregulates the pro-inflammatory immune response via adenylate cyclase. CB2
couples predominantly to Gαi/o, resulting in adenylyl cyclase inhibition (b) The mitogen-activated
protein kinase (MAPK) pathway. CB2 βγsubunit mediated activation of the MAPKs extracellular
regulated kinase (ERK1/2), p38 and janus-kinase (JNK)(86, 97). The CB2 receptor is coupled
with Gαi/o and Gαq (G protein-activating phospholipase C and G protein-increasing cytosolic Ca2+)
(94).
In the cardiovascular system, cannabinoid receptors are located in the myocardium,
vascular endothelial and smooth muscle cells, as well as circulating blood cells (83). Both CB1
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and CB2 receptor signaling modulate remote ischemic preconditioning-induced cardio protection
(98). Endocannabinoids overproduced during various forms of IR injury have been proposed to
protect against myocardial IR injury and to contribute to the ischemic preconditioning effect of
endotoxin, heat stress, or brief periods of ischemia, while these lipid mediators may also mediate
the cardiovascular dysfunction in these pathologies (99).
In a whole animal model of myocardial IR injury induced by coronary
occlusion/reocclusion in anesthetized mice, the protective role of CB2 but not CB1 receptor
activation was determined (8). Cannabinoid receptor 2 could potentially mediate protection
against the four phases after resuscitation (thought to occur depending on the degree and duration
of organ ischemia): 1. first 24hours after the event-a microcirculatory dysfunction from the
multifocal hypoxia leads to rapid release of toxic enzymes and free radicals into the
cerebrospinal fluid and blood; 2. 1 to 3 days- cardiac function and systemic function improve,
but intestinal permeability increases predisposing the patient to sepsis syndrome leading to
multiple organ dysfunction syndrome; 3. Days after cardiac arrest-a serious infection may occur,
and the patient declines rapidly, and; 4. The patient eventually dies (48). “Myocardial stunning”
classically defined as temporary mechanical dysfunction persisting after episodes of ischemia
and reperfusion with the absence of irreversible histological damage is also responsive to
therapeutic initiatives, namely inotropic therapy or even antioxidants or calcium antagonists for
implementing prevention strategies (100).
In addition to the cell-surface cannabinoid receptors, there is growing evidence that the
intracellular peroxisome proliferator-activated receptors (PPARs) are cannabinoid targets (101).
There are other non-CB1/CB2 receptors—such as GPR55, GPR119 and TRPV1 that are
phylogenetically unrelated to the CB1 or CB2 receptors but have the ability to respond to

36

endocannabinoids (102). PPARγ is a nuclear hormone receptor that regulates gene expression as
a ligand-activated transcription factor and, in the central nervous system, is expressed on
oligodendrocytes and astrocytes as well as neurons in multiple brain areas (103). WIN55 has
been reported to reduce inflammation in murine brain ECs through PPARγ, independent of CB1
and CB2. This mechanism needs further exploration (104) as nuclear transcription factors play an
important role in the regulation of initiation and resolution of the inflammatory process (Figure
6) (105). Direct binding of PPARs and the indirect effect of these receptors stimulate production
of antioxidant enzymes and inhibit NFkβ (105). Activated PPARγ with endogenous or synthetic
ligands can not only directly combine with the p50/p65 dimer and form a new complex that
downregulates the NFkβ signaling pathway but also upregulate the expression of IkBα and
indirectly inhibit the transcriptional activity of NFkβ (106).
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Figure 6. Cross-talk between PPARs and TLRs and NFkβ. Adapted from (105)
C. Anti-inflammatory properties of CB2
The first record of medical application of the strong anti-inflammatory effect of cannabinoids
comes from the world’s oldest pharmacopoeia, which was found in China (82).
Endocannabinoids mediate inflammation by regulating cytokines at different steps throughout
the inflammatory response (88). CB2 receptors are expressed mostly in the immune system,
including the thymus, spleen, lymphatic nodes, and circulating leukocytes, where they mediate
cytokine release (82). Levels of CB2 expression varies among different immune cell populations,
with B lymphocytes expressing the highest levels followed by macrophages, monocytes, natural
killer (NK) cells, and polymorphonuclear cells, in that order (91). An important development has
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been the identification of low levels of CB2 receptor expression in tissues previously thought to
be devoid of these receptors. These include specific regions of the brain (
Figure 7), spinal cord and dorsal root ganglia, neurons in the myenteric and submucosal
plexus of the enteric nervous system, in myocardium or cardiomyocytes (Figure 8), human
vascular smooth muscle and endothelium, activated hepatic stellate cells, Kupffer cells, in
reproductive organs/cells, colonic epithelial cells, bone, mouse and human exocrine and
endocrine pancreas, and in various human tumors (107). An interesting biologic property of CB2
receptors is their high inducibility, with CB2 mRNA levels often increasing as much as 100-fold
following nerve injury or during inflammation (108).

Figure 7. Brain CB2 expression and function and association with neuropsychiatric and
neurological diseases. Adapted from (109).
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Figure 8. Mapping of cannabinoid-sensitive receptors and eCBs in the heart (97).
A large body of preclinical research demonstrates the effectiveness of cannabinoids in rodent
models of acute and chronic inflammatory pain, as well as neuropathic pain (88). The
inflammatory response to insult must be tightly regulated in order to minimize damage to healthy
tissues. Thus, in addition to proinflammatory cytokines, active immune cells produce and
release anti-inflammatory mediators, including IL10, which are regulated by the
endocannabinoid system (88). Accumulating evidence supports the development of selective
CB2 receptor agonists for the management of acute tissue injury associated with inflammation
(such as myocardial infarction, stroke, or organ transplantation) (83). Since CB2 activation
dampens inflammatory responses in the absence of psychotropic effects, it has the potential to
serve as a molecular target for attenuating inflammation linked to pathogenic disorders (91).
Consistent with the protective role of CB2 receptor activation, CB2 -/- mice develop increased IR
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induced tissue damage and proinflammatory phenotype (8). Selective activation of the CB2
receptor a few minutes before reperfusion markedly improves myocardial infarction (110).
Mechanistic investigations reveal that the protective effect of CB2 receptor may ascribe to
reduction of cardiac leukocyte recruitment, reduction of superoxide generation, or increase of
ERK1/2 and STAT-3 phosphorylation (37). CB2 signaling in the heart and vasculature may
activate cardioprotective mechanisms and limit inflammation (Figure 9) (107). Evidence from in
vitro and in vivo models suggests that CB2 activation might reduce atherosclerotic inflammation
(110). CB2 receptor stimulation limits hepatic injury by decreasing the expression of ICAM-1,
CVAM-1, neutrophil infiltration, TNFα, chemokine (MIP-1α and MIP-2) levels, and lipid
peroxidation. The decrease in lipid peroxidation can be secondary to the decrease of
inflammatory cell infiltration and activation (8). However, the lack of highly selective CB2
receptor antibodies limits interpretation of some studies. Thus, the use of stringent negative
controls is crucial for the correct detection and quantification of protein targets (88).

Figure 9. Cardiac impact of cannabinoid receptors. Adapted from (97).
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Collectively, a number of studies suggest that exogenous cannabinoids elicit a shift in the
cytokine expression profile from that which is Th1 proinflammatory to one that is Th2 antiinflammatory and that the CB2 receptor may be linked to this effect (111). It has been observed
that the CB2 agonist HU-308 attenuated hepatic ischemia/reperfusion injury by decreasing levels
of TNFα, MIP-1α and MIP-2 in serum and liver homogenates (112). Cannabinoid CB2 receptor
knockout (CB2 -/-) mice are fertile, care for their offspring, and have a similar phenotype as their
wild-type littermates (8), which shows CB2 knockout is not lethal.
Possible mechanisms between systemic inflammation and hemodynamics have not been fully
characterized but direct effects of inflammatory mediators on the contractility of the myocardium
and vascular smooth muscle have been suggested (113). Though WIN55 has been demonstrated
to have anti-inflammatory and anti-oxidative effects in inflammatory or ischemia diseases
independent of its hypothermic effects, previous studies could not exclude other effects (114).
Recent studies have indicated that activation of CB2 leads to an anti-inflammatory response;
therefore, the beneficial effects of WIN55 following resuscitation may be related to both CB1
and CB2 receptor activation.
IV.
Research Objectives
Cannabinoids produce hypothermia in normal rats through the activation of central CB1
receptors. WIN55, the nonselective cannabinoid CB1/CB2 receptor agonist, produced
hypothermia in a dose-dependent manner when injected intramuscularly. The body temperature
reduced from 37 to 34oC, 60 to 180 mins post injection and hypothermia was maintained up to 5
hours. The effect was completely blocked by the selective CB1 antagonist SR141716A (115,
116). CB2 receptor ligands have potential therapeutic applications as immunomodulators for the
treatment of inflammation (117). Hypothesized effects of WIN55 summarized in Figure 10.
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Figure 10. WIN55, 212-2 can be coupled to either CB1 or CB2 with different functional
consequences.
The effects of WIN55 were investigated initially in our rat model of CA and CPR. WIN55
was selected based on the following reasons: 1) the described hypothermia effect of CB1 agonist
is convincing and well documented, 2) it is highly selective for cannabinoid receptors and
interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in
thermoregulatory areas of the central nervous system and therefore decreases body temperature
via a central mechanism (119), 4) It has been shown to be neuroprotective (120) and 5) It has
been demonstrated in both mice and rats that the CB2 receptor activation effects of WIN55 have
significant anti-inflammatory effects (121-123). CB2 expression has been demonstrated in cardiac
myocytes and endothelial and smooth muscle cells of coronary arteries (84).
Hypothesis: Cardiac arrest will cause mitochondrial dysfunction and increase plasma
concentrations of TNFα, IL6 and IL10. IM Administration of SR141716A before VF+CPR
followed by infusion of WIN55 5 min after ROSC will prohibit the release of inflammatory
mediators caused by cardiac arrest via the CB2 receptor.
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CHAPTER 2: Materials and Methods

I.

Reagents

Lipopolysaccharide (LPS), sodium chloride (NaCl), (R)-(+)-WIN55,212-2 mesylate salt,
polysorbate 80, dimethyl sulfoxide, DTT (Pro#1000748546), iodoacetamide (Pro#122270250),
LC-MS/MS grade water, methanol, acetonitrile and common laboratory chemicals were
purchased from Sigma Aldrich (St. Louis, MO). Pierce Trypsin Protease, MS grade (Pro#
90057), Pierce BCA Protein Assay Kit (Pro# 23250) and Formic Acid Optima LC/MS (A11-50)
were purchased from Fisher Scientific (Waltham, MA). A TMT10plex Isobaric Label Reagent
Set plus TMT11-131C Label Reagent (A34808) was purchased from Thermo Scientific
(Rockford, IL). Dulbecco’s Modified Eagle Medium (DMEM), 100x Penicilin/Streptomycin and
1M HEPES were obtained from Life Techonologies, Gibco (Waltham, MA). Heat inactivated
Fetal Bovine Serum (FBS) was from Atlanta Biologicals (Flowery Branch, GA). CB1 receptor
antagonist SR141716A and (+)-WIN55,212-2 (mesylate) were purchased from Cayman
Chemicals (Ann Arbor, MI).
II.

In vivo-Mitochondria

Guanghui Zheng performed surgical technique, Xianfei Ji performed mitochondrial isolation
and measurement and helped draft manuscript, Jeremy Thompson trained Xianfei Ji and Jennifer
Bradley on all mitochondrial techniques, Rabiya Shabnam ran ETC assay, Jennifer Bradley
analyzed all data and drafted manuscript and Qun Chen, Edward Lesnefsky and Wanchun Tang
reviewed data and manuscript drafts. This study was approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University. Animal care and handling were in
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accordance with the Guide for the Care and Use of Laboratory Animals and the ARRIVE
guidelines.
Animal Preparation
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). End-tidal
CO2 (ETCO2) was continuously monitored with a side-stream infrared CO2 analyzer (Capstar100 Carbon Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II electrocardiogram
(ECG) was monitored continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ,
USA) inserted into the descending aorta measured arterial pressure. A thermocouple microprobe
(9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein
measured blood temperature. Another PE-50 catheter advanced into the right atrium measured
right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN)
advanced into the right atrium was utilized to advance a pre-curved guidewire into the right
ventricle to induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated
surgical board. ECG, aortic and right atrial pressures, ETCO2, and blood temperature were
continuously recorded on a personal computer–based data acquisition system supported by
WINDAQ software (DATAQ, Akron, OH).
Experimental Procedures
Animals were randomized into 4 groups (n=6 each group): 1) Sham (underwent surgery, no
VF or CPR), 2) VF (VF only for 8 min), 3) VF+CPR (VF 8 min + CPR 8 min, no defibrillation)
and 4) Return of Spontaneous Circulation (ROSC 1 hr) (VF 8 min, CPR8 min, defibrillation, and
observe 1 hr after ROSC) (Figure 11). Mechanical ventilation was established at a tidal volume
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of 0.60 mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then
induced with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the
right ventricular endocardium. Current flow continued for 3 min to prevent spontaneous
defibrillation. After 8 min of untreated VF, precordial chest compressions, together with
mechanical ventilation, were initiated using a pneumatically driven mechanical chest
compressor. Precordial chest compressions were maintained at a rate of 200/min and
synchronized to provide a compression/ventilation ratio of 2:1 with equal compression-relaxation
for 8 min. Defibrillation was attempted with up to three 4-J counter shocks. ROSC was defined
as the return of supraventricular rhythm with a mean aortic pressure (MAP) above 50 mm Hg for
5 min.

Figure 11. In vivo-Mitochondria Experimental Protocol-N=6 for each group. Sham is time
zero control.
Cardiac mitochondria were isolated by a method previously described with slight
modifications (124, 125). Hearts were removed and placed into buffer A [100 mM KCl, 50 mM
3-(N-morpholino) propanesulfonic acid (MOPS), 1 mM EGTA, 5 mM MgSO4-7 H2O, and 1
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mM ATP, pH 7.4] at 4°C. Cardiac tissue was finely minced and placed in buffer A containing
0.2% bovine serum albumin (BSA) and homogenized with a polytron tissue processor
(Brinkman Instruments, Westbury, NY) for 2.5 s at a rheostat setting of 14. The polytron
homogenate was centrifuged at 2,200 rpm for 10 min, supernatant was saved for isolation of
subsarcolemmal mitochondria (SSM), and the pellet was washed. Combined supernatants were
centrifuged at 5,000 rpm for 10 min to sediment SSM. Interfibrillar mitochondria (IFM) were
isolated by incubation of skinned myofibers, obtained after polytron treatment (2.5 sec at a
setting of 14), with 5 mg/g (wet weight) trypsin for 10 min at 4°C. SSM and IFM were washed
twice and then suspended in 100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA. Mitochondrial
protein concentration was measured by the Lowry method using BSA as a standard (125).
Brain mitochondria were isolated by a method previously described with slight modifications
(126). Brain (cerebrum) was rapidly removed and homogenized at 4οC in 10ml of isolation
buffer B (215mM mannitol, 75mM sucrose, 20 mM HEPES, 1mM EGTA, pH 7.4) containing
5mg of the bacterial protease type VIII (Subtilsin A). Brain homogenates were brought to 30 ml
and then centrifuged at 12,000 rpm for 10 min. The pellet was resuspended in 10 ml of buffer C
(buffer B+1mg/ml bovine serum albumin) and centrifuged at 2,420 rpm for 10 min. The
mitochondrial pellet was resuspended in 10 ml of buffer C and centrifuged at 2,420 rpm for 10
min. Combined supernatants were centrifuged at 9,000 rpm for 10 min. The pellet was then
resuspended in 3 ml buffer C, and centrifuged at 9,000 rpm for 10 min. The pellet was
resuspended in 2 ml buffer B, and centrifuged at 9,000 rpm for 10 min. Finally, the
mitochondrial pellet was resuspended in 100 μl buffer B.
Measurements
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Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at
30°C as previously described (127, 128) using glutamate (20 mM) (complex I substrate),
succinate (20 mM) (complex II substrate), plus 7.5 mM rotenone and N,N,N’,N’ tetramethyl pphenylenediamine (TMPD; 1 mM)-ascorbate (10 mM) (complex IV substrate) + rotenone
(Figure 12). Maximal ADP-stimulated respiration (2 mM ADP) was determined. Mitochondria
were used within 6 hrs after isolation.

Figure 12. Mitochondria Electron Transport Chain Complex substrates and inhibitors.
Adapted from (22)
Enzyme activities were measured spectrophotometrically in detergent-solubilized frozenthawed mitochondria using previously described methods (129): NADH-ubiquinone
oxidoreductase, rotenone- sensitive (complex I=340nm), NADH-ferricyanide reductase
(NFR=340nm); succinate-ubiquinone oxidoreductase, thenoyltrifluoroacetone sensitive (complex
II=600nm); ubiquinol-cytochrome c oxidoreductase, antimycin A sensitive (complex III=550
and 600nm); and citrate synthase (=412nm). Frozen-thawed mitochondria were solubilized at a
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final protein concentration of 1 μg/μl in 0.5% cholate in MSM/EDTA buffer, pH 7.4 (220 mM
mannitol, 70 mM sucrose, 5 mM MOPS, 2 mM EDTA) (130).
Calcium retention capacity (CRC) was used to assess calcium-induced MPTP opening as
previously described (131) in mitochondria (125 μg/ml) incubated in medium containing 150
mM sucrose, 50 mM KCl, 2 mM KH2PO4, 5 mM succinate, in 20 mM Tris·HCl, pH 7.4, by
sequential pulses of 5 nmol calcium. Extramitochondrial Ca2+ concentration was recorded with
0.5 μM calcium Green-5N (Life Technologies City State), and fluorescence monitored with
excitation and emission wavelengths at 500 and 530 nm, respectively (131). The calcium
retention capacity CRC assay measures the susceptibility to opening of the permeability
transition pore; and is performed in a non-acidic environment.
III.

In vivo-Proteomics

Fenglian He and Christine Moore performed surgical technique, Gea-Ny Tseng performed
tissue lysate preparation and Poochon Scientific LLC performed proteomic analysis. Jennifer
Bradley reviewed proteomic results focusing on S100A8/A9 expression (132) and found it
increased within LV Apex Epicardium following CA and CPR. This study was approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University. Animal
care and handling were in accordance with the Guide for the Care and Use of Laboratory
Animals and the ARRIVE guidelines.
Animal Preparation
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). ETCO2
was continuously monitored with a side-stream infrared CO2 analyzer (Capstar-100 Carbon
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Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored
continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the
descending aorta measured arterial pressure. A thermocouple microprobe (9030-12-D-30,
Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein measured blood
temperature. Another PE-50 catheter advanced into the right atrium measured right atrial
pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) advanced
into the right atrium was utilized to advance a pre-curved guidewire into the right ventricle to
induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated surgical board.
ECG, aortic and right atrial pressures, ETCO2, and blood temperature were continuously
recorded on a personal computer–based data acquisition system supported by WINDAQ
software (DATAQ, Akron, OH).
Experimental Procedures
Animals were randomized into 3 groups: 1) Sham (underwent surgery, no VF or CPR) (n=4),
2) CPR (VF 8 min + CPR 8 min, defibrillation and ROSC) (n=4), 3) Norm (nothing done to
animal) (n=3) (Figure 13). Mechanical ventilation was established at a tidal volume of 0.60
mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then induced
with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the right
ventricular endocardium. Current flow continued for 3 min to prevent spontaneous defibrillation.
After 8 min of untreated VF, precordial chest compressions, together with mechanical
ventilation, were initiated using a pneumatically driven mechanical chest compressor. Precordial
chest compressions were maintained at a rate of 200/min and synchronized to provide a
compression/ ventilation ratio of 2:1 with equal compression-relaxation for 8 min. Defibrillation
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was attempted with up to three 4-J counter shocks. ROSC was defined as the return of
supraventricular rhythm with a MAP above 50 mm Hg for 5 min.

Figure 13. In vivo-Proteomics Experimental Protocol
Measurements
Once ROSC was reached Christine Moore or Dr. Tseng removed the heart for further
analysis. Samples sent to Poochon Scientific were labeled Left Ventricle Apex epicardial
(LV Apex EPI) (Figure 14).
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Figure 14. LV Apex Epi- Samples sent to Poochon Scientific for further analysis were labeled
LV Apex Epi from Dr. Tseng’s laboratory. Adapted from (133).
General Protocol of protein lysate preparation performed by Dr. Tseng’s laboratory
RIPA buffer: 20mM Tris-HCL pH7.4, 150mM Na\Cl, 1mM EDTA, 1% Triton-X100, 1%
sodium deoxycholate, 0.1% SDS with freshly added PMSF to 1mM and with freshly added
aprotinin and leupeptin to 5ug/ml was prepared just before use. The left ventricular (LV) apex
was removed and placed in RIPA on ice for 10 min before homogenizing. Tissue was kept on ice
during homogenization until tissue was liquified. Then liquified tissue lysate was centrifuged at
13,000 rpm for 3min at 4°C. Clear supernatant was transferred to new clearly labelled tubes for
shipment to Poochon Scientific (134).
BCA Assay performed by Poochon Scientific
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Tissue lysate samples were thawed at room temperature and a precipitation (cloud) was
observed. 20 µl of 10% SDS was added to the sample and heated at 95°C for 10 minutes. After
treatment the lysate became clear. Protein concentration of supernatant was determined by a
BCA™ Reducing Reagent compatible assay kit from Thermo Scientific (Rockford, IL). The
BCA Protein Assay is a popular method for colorimetric detection and quantitation of total
protein (135). The assay was read at an optical density (OD) of 562nm. One major advantage of
the BCA assay is that it produces a linear response curve. This response curve allows accurate
determination of unknown protein concentrations and provides a higher dynamic range than
other standard assays (135).
TMT-11plex labeling performed by Poochon Scientific
100 µg of protein lysate was taken from each sample for in-solution trypsin digestion.
Predigestion was ran along with digested samples on SDS-PAGE and stained to check digestion
efficiency. Isobaric labeling was performed using a commercial TMT10plex Isobaric Label
Reagent Set plus TMT11-131C Label Reagent kit according to the product manual and samples
were labeled as described in Table 1. The 11 labeled peptide mixture was then dried in a vacuum
concentrator and stored at -80 ºC for the next step.
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Table 1. Summary of 11 cell pellet sample labeling
Sample Label

Description

TMT-tag

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11

Norm_1
Norm_2
Norm_3
CPR_1
CPR_2
CPR_3
CPR_4
Sham_1
Sham_2
Sham_3
Sham_4

126
127C
127N
128C
128N
129C
129N
130C
130N
131
131C

TMT Quantification (ratio)
126/131
127C/131
127N/131
128C/131
128N/131
129C/131
129N/131
130C/131
130N/131
131/131
131/131-C

Fractionation of labeled peptides by basic reversed phase UHPLC
Dried labeled peptides were resuspended in 10 mM TEABC. Labeling efficiency was
determined before fractionation by analysis of a small sample aliquot (1%). A minimum labeling
efficiency of 95% was required. The fractionation of TMT-10plex labeled peptide mixture was
carried out using an Agilent AdvanceBio Column (2.7 µm, 2.1 x 250 mm) at Solvent A (10 mM
TEABC, pH 8.0) and an Agilent UHPLC 1290 system. Separation was performed by running a
gradient of Solvent B (10 mM TEABC, pH 8.0, 90% ACN) and Solvent A (10 mM TEABC, pH
8.0) at a flow rate 250 µL/min. Elute fractions were collected into a 96-well plate using a 1260
series auto-sample fraction collector. The 96 elute fractions were further combined into 24
fractions according to collection time (e.g. Ax/Cx/Ex/Gx, and Bx/Dx/Fx/Hx, A/B/C/D/E/F/G/H
represents column, x represents row 1 through row 12) for LC/MS/MS analysis.
Nanospray LC/MS/MS analysis and database search performed by Poochon Scientific
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LC/MS/MS analysis was carried out using a Thermo Scientific Q-Exactive hybrid
Quadrupole-Orbitrap Mass Spectrometer and a Thermo Dionex UltiMate 3000 RSLCnano
System. Each peptide fraction from a set of 24 fractions was loaded onto a peptide trap cartridge
at a flow rate of 5 μL/min. Trapped peptides were eluted onto a reversed-phase 20 cm C18
PicoFrit column (New Objective, Woburn, MA) using a linear gradient of acetonitrile (3-36%) in
0.1% formic acid. The elution duration was 110 min at a flow rate of 0.3 μL/min. Eluted peptides
from the PicoFrit column were ionized and sprayed into the mass spectrometer, using a
Nanospray Flex Ion Source ES071 (Thermo) under the following settings: spray voltage, 1.8 kV,
Capillary temperature, 250°C. 24 fractions were analyzed sequentially. The Q Exactive
instrument was operated in the data dependent mode to automatically switch between full scan
MS and MS/MS acquisition. Survey full scan MS spectra (m/z 300−1800) was acquired in the
Orbitrap with 70,000 resolutions (m/z 200) after accumulation of ions to a 1 × 106 target value
based on predictive automatic gain control (AGC). Dynamic exclusion was set to 20 s. The 15
most intense multiply charged ions (z ≥ 2) were sequentially isolated and fragmented in the
octopole collision cell by higher-energy collisional dissociation (HCD) using normalized HCD
collision energy 28% with an AGC target 1×105 and a maximal injection time of 100 ms at
17,500 resolutions. MS Raw data files (24 files from 24 fractions) were searched against the
Rattus norvegicus (Rat) protein sequences database obtained from UniprotKB website using
Proteome Discoverer 1.4 software (Thermo, San Jose, CA) based on the SEQUEST and
percolator algorithms. False positive discovery rates (FDR) was set on 5%. A Proteome
Discoverer Report was generated containing all assembled proteins with peptides sequences and
peptide spectrum match counts (PSM#) and TMT-tag based quantification ratio.
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TMT-tag based quantification was used to determine the relative abundance of proteins
identified from each set of 11 samples using one TMT-10plex. The TMT-Tag-131 was used as
the common denominator for calculation of the ratio (e.g. A1-TMT-tag-126 versus sample 11Tag131). Relative abundance of proteins was normalized based on the sum of ratios (Figure 15
and Figure 16).

Figure 15. Poochon Scientific Schematic of Experimental Workflow. One TMT set labeled
11 samples. Procedures included preparation of lysates, trypsin digestion, TMT-ll plex of
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labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC,
nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization
and data analysis.

Figure 16. Poochon Scientific Schematic of Experimental Workflow. One TMT set labeled
11 samples. Procedures included preparation of lysates, trypsin digestion, TMT-ll plex of
labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC,
nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization
and data analysis.
Analysis performed by Jennifer Bradley
Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes and biological
pathways, was used to map pathways from proteins identified. NCBI accession numbers (136)
(4,997) were converted to Kegg (137) (3,195). One KEGG pathway was identified to have been
significantly regulated by CA/CPR (138). NCBI terms were converted to Go terms by Biological
DataBase network with p values obtained by Poochon Scientific for Revigo analysis. Revigo
uses a clustering algorithm to sort GO terms by similarity into similar biological processes (139).
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IV.

In vitro-WIN55

Yanyan Wang trained Jennifer Bradley on in vitro techniques, Jennifer Bradley performed
cell culture with reagents prepared by Yanyan Wang, ELISA, analyzed all data and drafted
SCCM 2020 abstract. Huiping Zhou and Wanchun Tang reviewed data and abstract drafts.
Mouse RAW 264.7 macrophage cells (ATCC, Rockville MD, USA) were plated into 60mm
dishes with a density of 10*105 cells/dish and incubated with DMEM containing 10%FBS,
1%PS overnight. Cell media was then changed to DMEM containing 1% FBS, 1%PS, and
incubated for 4hrs (140, 141). They were then pretreated with WIN55 (5 μM) (142) for 2 hrs,
then treated with LPS (12.5 ng/mL) for 6hrs and 24 hrs. At the end of treatment, culture media
was collected and centrifuged at 14,000 x rpm for 1 min (143). Media protein levels of TNFα,
IL6, and IL1β were quantified using commercial enzyme-linked immunosorbent assays
(ELISAs) (R&D Systems, Minneapolis, MN, USA) (144). Concentrations were expressed as
pg/mL.
V.

In vivo-WIN55

Yan Xiao, Jadd Khoraki and Jennifer Bradley performed surgical technique. Jennifer Bradley
performed ELISA and analyzed all dissertation data and Wanchun Tang reviewed. This study
was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth
University. Animal care and handling were in accordance with the Guide for the Care and Use of
Laboratory Animals and the ARRIVE guidelines.
Animal Preparation
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). ETCO2
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was continuously monitored with a side-stream infrared CO2 analyzer (Capstar-100 Carbon
Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored
continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the
descending aorta measured arterial pressure and was utilized for blood withdrawal. A
thermocouple microprobe (9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted
into the left femoral vein measured blood temperature. Another PE-50 catheter advanced into the
right atrium measured right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical
Care, Bloomington, IN) advanced into the right atrium was utilized to advance a pre-curved
guidewire into the right ventricle to induce VF. Another PE-50 catheter inserted into the right
femoral vein was utilized for drug infusion (Figure 17). All catheters were flushed intermittently
with saline containing 2.5 IU/mL of crystalline bovine heparin (145). Aortic blood temperature
was maintained at 37°C ± 0.5°C by a heated surgical board. ECG, aortic and right atrial
pressures, ETCO2, and blood temperature were continuously recorded on a personal computer–
based data acquisition system supported by WINDAQ software (DATAQ, Akron, OH).
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Figure 17. In vivo-Study Design
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Figure 18. In vivo-WIN55 Experimental Protocol
Experimental Procedures
Animals were randomized into 2 groups (Figure 18) : 1) 2% Tween 80 (VF 6 min + CPR 8
min, defibrillation and ROSC followed by infusion) (n=3), 2) SR141716A+WIN55 (IM
Administration of SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide)
before VF 6 min + CPR 8 min, defibrillation and ROSC followed by infusion) (n=6). At 5
minutes after ROSC, either WIN55 (1 mg/kg/h) or vehicle (2% Tween-80 in 0.9% NaCl
solution) was administered by continuous intravenous infusion with a syringe pump (Genie
Touch; Kent Scientific Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114). Mechanical
ventilation was established at a tidal volume of 0.60 mL/100g of body weight, a frequency of
100 breaths/min, and FiO2 of 1.0. VF was then induced with a progressive increase in 60-Hz
current to a maximum of 3.5 mA delivered to the right ventricular endocardium. Current flow
continued for 3 min to prevent spontaneous defibrillation. After 6 min of untreated VF,
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precordial chest compressions, together with mechanical ventilation, were initiated using a
pneumatically driven mechanical chest compressor. Precordial chest compressions were
maintained at a rate of 200/min and synchronized to provide a compression/ ventilation ratio of
2:1 with equal compression-relaxation for 8 min. Defibrillation was attempted with up to three 4J counter shocks. ROSC was defined as the return of supraventricular rhythm with a MAP above
50 mm Hg for 5 min.

Figure 19. SR141716A is an antagonist for CB1 (111)
Measurements
Hemodynamics and myocardial function
Electrocardiogram, aortic and right atrial pressures, blood temperature, and ETCO2 values
were continuously recorded on a personal computer-based data-acquisition system supported by
WINDAQ software (DATAQ, Akron, OH). At baseline, 2 and 4 hours after ROSC, EF, CO, and
myocardial performance index (MPI) were measured by echocardiography (HD11XE; Philips
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Medical Systems, Eindhoven, Netherlands) with a 12.5 Hz transducer. EF and CO are adopted to
estimate the myocardial contractility; MPI is adopted to estimate left ventricular diastolic
function. The MPI, which combines time intervals related to systolic and diastolic functions
reflecting the global cardiac function, is also calculated using the formula (a − b)/b, where
a = mitral closure-to-opening interval (time interval from cessation to onset of mitral inflow) and
b = ET (aortic flow ejection time, obtained at the left ventricle outflow tract) (145).
ELISA Analysis
One ml blood samples were collected at baseline, 2 and 4 hours after ROSC. After
centrifugation (2,100×g, 10 min, 4°C) (146), plasma was removed and stored at −80°C for
further ELISA analysis. Protein levels of TNFα, IL6, IL10 (R&D Systems, Minneapolis, MN,
USA) S100A8 and cardiac troponin I (TNNI3) (LifeSpan BioSciences, Seattle, WA, USA) were
quantified using commercial ELISA kits. ELISA measurement was performed following
manufacturer’s instructions.
VI.

Statistical Analysis

GraphPad PRISM version 9.0 for Windows (GraphPad Software Inc., San Diego, CA) was
used to conduct analyses. Data are expressed as mean ± standard deviation (SD). Differences
between greater than three groups were compared using a one-way analysis of variance
(ANOVA) (Tukey or Bonferonni test for multiple comparisons). When only two groups were
present, an unpaired student’s t-test was conducted. A p-value of <0.05 was considered
statistically significant.
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CHAPTER 3: Cerebral and myocardial mitochondrial injury differ in a rat model of
cardiac arrest and cardiopulmonary resuscitation

RATIONALE
Mitochondria are both targets and sources of damage during ischemia and reperfusion
(22, 147). Following ischemia and reperfusion, mitochondrial dysfunction involves the increased
production of reactive oxygen species (ROS), alteration of electron transfer activity, opening of
the mitochondrial permeability transition pore (MPTP) and cytochrome c release (148-155).
Ischemia damages the electron transport chain (ETC) (156) and decreases the rate of oxidative
phosphorylation (OXPHOS) (157, 158). However, little is known regarding the effects of VF and
CPR consistent with salvage by resuscitation on brain and heart mitochondrial function.
We hypothesize that mitochondrial damage differs between the brain and heart. Brain
mitochondria are more vulnerable to ischemia and suffer reperfusion injury in addition to
ischemic alterations, resulting in diminished overall mitochondrial respiration following
resuscitation (159). The purpose of this study was to measure mitochondrial function following
cardiac arrest (CA) with and without cardiopulmonary resuscitation (CPR) using OXPHOS, ETC
enzyme activity and calcium retention capacity (CRC) as an index of susceptibility to MPTP
opening.
RESULTS
Body weight, blood temperature, ETCO2 and CPP during CPR were not different between
VF+CPR and ROSC 1hr (Table 2). The maximal rate of OXPHOS was measured stimulated by
2 mM ADP with glutamate as a complex I substrate. Oxidative phosphorylation was decreased
by CA in brain and remained depressed through CPR and ROSC (Figure 20). Cardiac
mitochondria were less susceptible to injury, with preserved OXPHOS until the reperfusion of
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ROSC in SSM (Figure 21) and preserved function throughout in IFM (Figure 22). As previously
described, SSM were more susceptible to injury than IFM (127, 150, 160). Inhibition of complex
I activity is one of the earliest alterations in mitochondrial function due to ischemia (161).
Maximal rate of OXPHOS stimulated by 2 mM ADP with TMPD-ascorbate as a complex IV
substrate was no different in brain compared to heart mitochondria (Table 3).
Table 2. Physiologic parameters
Variables
Body Weight (g)
Blood temperature (οC)
ETCO2 (mmHg)
CPP (mmHg)

VF+CPR

ROSC 1hr

487.8±19.2
36.7±0.4
25.5±3.1
27±3

487.2±6.4
36.7±0.3
25.9±4.9
27.5±2.9

Mean ± SD, Unpaired t test, p>0.05 vs VF+CPR N=6 in each group.
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Figure 20. BM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C.
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA,
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor.
Oxidative phosphorylation with glutamate as a complex I substrate was decreased by cardiac
arrest in brain, and remained depressed through cardiopulmonary resuscitation. Mean ± SD,
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group.
My contribution (a) design of the experiments (c) Analysis of the data.
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Figure 21. SSM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C.
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA,
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor.
Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS until the
reperfusion of ROSC in SSM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05
**p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the
experiments (c) Analysis of the data.
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Figure 22. IFM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C.
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA,
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor.
Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS
throughout in IFM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01
***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c)
Analysis of the data.
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Table 3. Mean Percent Change of Rate of oxidative phosphorylation in brain and heart
mitochondria using TMPD as complex IV substrate.
2mM ADP
VF
VF+CPR
ROSC 1hr

BM
Down 38±37.3
Down 21±9.4
Down 24±12

SSM

IFM

Down 28±14.3
Down 17±10.2
Down 33±29.7

Down 23±15.8
Up 33±17.3
Down 39±23.7

Mean ± SD, p>0.05 vs Sham rates: BM 2672±666.8; SSM 5844±1539.6; IFM 3968±1257.6
nAO/min/mg mitochondrial protein; N=6 in each group. Oxygen consumption in mitochondria
was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a
solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml
bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP,
TMPD-ascorbate (complex IV substrate) was added as an electron donor.

Enzyme activity of ETC complexes was measured to identify the primary sites most
affected by ischemia within the ETC. CA resulted in sustained damage to complex I in brain
mitochondria (Figure 23). NADH:ferricyanide oxidoreductase activity decreased following
ROSC, suggesting that reperfusion caused damage to the NADH oxidase portion of the complex
(Figure 24). In contrast, complexes II and III remained unaltered (Table 4). In this rat model of
CA and CPR, brain complex I is more vulnerable to damage during ischemia and reperfusion
than complex II or complex III. Complex I in brain is also more susceptible to damage than
complex I in heart.
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Figure 23. BM enzyme activity confirmation of Complex I damage. CA resulted in sustained
damage to complex I in brain mitochondria. Mean ± SD, One-way ANOVA, Tukey Post-hoc
*p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the
experiments (c) Analysis of the data.
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Figure 24. BM enzyme activity of NADH:ferricyanide oxidoreductase-decreased following
return of spontaneous circulation. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05
**p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the
experiments (c) Analysis of the data.
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Table 4. Brain and heart mitochondria Electron Transport Chain Results.
Complex II

BM

SHAM
VF
VF+CPR
ROSC 1hr

274.8±69.3
230.2±67.9
223±39.6
178±70.1

Complex III

BM

SHAM
VF
VF+CPR
ROSC 1hr

3572±739.4
2896.4±672.5
3039.8±365.8
3043±698.3

SSM

IFM

101.4±47.9
-70±10.4
89.6±14
SSM

119.6±28.2
-150±26
128.4±36.6
IFM

4128.2±1251.7
-1869.2±515*
2501.6±1543.9

4974±554.3
-4722±1065.7
4045.6±581.5

Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham. Enzyme
activity is mU/mg mitochondrial protein. N=5 in each group.
In the heart, VF+CPR decreased complex I activity in SSM and remained low during the
first hour of ROSC (Figure 25). NADH:ferricyanide oxidoreductase activity was decreased
concomitant with the decrease in complex I activity, suggesting that the site of damage is in the
NADH oxidase portion of the complex (Figure 26). In contrast, IFM were relatively free of
damage with a non-significant trend of decreased complex I activity (Figure 27). Complexes II
and III did not sustain damage in IFM (Table 4).
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Figure 25. SSM enzyme activity confirmation of Complex I damage. VF+CPR decreased
complex I activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01
***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c)
Analysis of the data.
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Figure 26. SSM enzyme activity of NADH:ferricyanide oxidoreductase-decreased NFR
activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs
Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
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Figure 27. IFM enzyme activity of Complex I. Mean ± SD, One-way ANOVA, Tukey Posthoc p>0.05 vs Sham N=5 in each group. My contribution (a) design of the experiments (c)
Analysis of the data.
Calcium retention capacity (CRC) in brain decreased rapidly and was abnormal
throughout CA and CPR (Figure 28), in contrast to heart CRC that only decreased following
ROSC in both SSM and IFM (Figure 29 and Figure 30). Thus, brain mitochondria are more
susceptible to MPTP opening compared to heart mitochondria. Furthermore, an increased
susceptibility to MPTP opening is already evident in brain mitochondria during the initial period
of CA.
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Figure 28. BM calcium retention capacity (CRC)-measured as an index of susceptibility to
MPTP opening. CRC in brain rapidly decreased, and was abnormal throughout CA and CPR.
Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in
each group. My contribution (a) design of the experiments (c) Analysis of the data.
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Figure 29. SSM calcium retention capacity (CRC)-measured as an index of susceptibility to
MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way
ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My
contribution (a) design of the experiments (c) Analysis of the data.
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Figure 30. IFM calcium retention capacity (CRC)-measured as an index of susceptibility to
MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way
ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My
contribution (a) design of the experiments (c) Analysis of the data.
DISCUSSION
Our experimental CA/CPR (145, 162, 163) model indicates that mitochondrial damage is
different between rat brain and heart. Brain mitochondria are more sensitive to global ischemia.
Heart SSM are minimally damaged whereas IFM remain intact. In contrast, mitochondrial
OXPHOS and ETC indicate that complex I is markedly decreased in brain. This is in line with
Borutaite et al. reporting a decrease in complex I activity after 20-25min of global no-flow
ischemia (161). Alleviation of complex I injury may be an important therapeutic target to reduce
brain injury during CA and CPR. Currently, no pharmacological treatment has been approved for
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neuroprotection after CA (9). Donnino et al’s characterization of mitochondrial injury after
cardiac arrest (COMICA) clinical trial demonstrated mixed results with mitochondrial injury
markers post-arrest. Pathways in humans remain incompletely characterized and need to be
studied further (34).
OXPHOS, with glutamate is used to assess the response of intact mitochondria to
ischemia (164). Ischemia leads to progressive injury to the ETC (22, 127) and ischemic
mitochondrial damage occurs more rapidly in SSM, which are located beneath the plasma
membrane, than in IFM, which are located between the myofibrils (127). SSM were more
susceptible to injury than IFM, which is consistent with previous studies (127, 150, 160). SSM
and IFM injury induced by 8 min of CA did not progress despite markedly reduced blood flow
and oxygen supply during 8 min of CPR. Results are less severe than studies of more prolonged
ischemia (15, 131, 150). Myocardial mitochondria show a markedly increased susceptibility to
opening of the MPTP following a more robust reperfusion resulting from one hour of ROSC.
There is a significant decrease in mitochondrial function following 25 min of stop-flow
myocardial ischemia (129). CPR is sufficient to interrupt or slow the ongoing ischemic insult
imposed on myocardial mitochondria, and possibly extends the period of mitochondrial viability
during early stages of CA.
The rate of OXPHOS was markedly decreased in brain mitochondria oxidizing complex I
substrate (Figure 20). A complex I defect occurs during cerebral ischemia or CA. This was
confirmed by enzyme activity measurement (Figure 23). Furthermore, the activity of
NADH:ferricyanide oxidoreductase (NFR) was decreased (127) (Figure 24). Ferricyanide is an
artificial electron acceptor that is reduced by the flavin mononucleotide cofactor in the NADH
dehydrogenase component of complex I (165). Complex I activity decreases during ischemia in
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cardiac mitochondria due to a decrease in the NADH dehydrogenase component likely due to
loss of the flavin mononucleotide coenzyme (156, 166-168). Damage to the NADH
dehydrogenase component of complex I can increase electron leak and ROS production,
contributing to brain damage after CA (168). Reperfusion of ischemic brain also leads to massive
generation of ROS (169). Activated microglia convert into a pro‑inflammatory (M1) phenotype
that obtains macrophage-like properties (such as antigen presentation) and generates several
pro‑inflammatory mediators (such as IL1 β, TNFα, and ROS) that can disrupt the blood brain
barrier (BBB) (9). Generation of ROS, including from complex I itself, can lead to complex I
damage (125, 129, 169). Development of ischemic acidosis during CA might also facilitate
flavoprotein dissociation, hindering electron transfer and impairing complex I activity (15).
Consistent with the decrease in NFR, ischemia induced loss of FMN may contribute (170).
Ischemia also damages complex I at sites more distal in the path of electron flow at iron sulfur
centers, including immediately proximal to the quinol binding site (129, 171). Complex I also
undergoes a conformational change from an active form to a “de-active” form (170). However,
the de-active form of complex I should be reactivated under conditions of the ETC assay.
Whether these potential contributing factors contribute to the beneficial effects of CPR remains
to be explored. In general, brain mitochondrial dysfunction following ischemia is associated with
impaired complex I activity.
Mitochondrial dysfunction after resuscitation from CA due to impaired electron transport
through the respiratory complexes of the ETC leading to decreased rates of OXPHOS is poorly
characterized in patients who achieve ROSC. ETC dysfunction reduces mitochondrial membrane
potential. Impaired OXPHOS leads to decreased generation of high energy phosphates. Direct
damage to mitochondria leads to diminished electron flow and increased ROS generation,
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favoring oxidative tissue injury. Damage to the mitochondrial inner membrane leads to
decreased membrane potential and favors cytochrome c release into the cytosol, which activates
cell death (14). Mitochondrial defects are associated with reduced ATP generation, metabolic
failure, altered signaling pathways, and induction of apoptosis.
Susceptibility of MPTP opening has been implicated as a key mechanism underlying both
necrotic and apoptotic cell death during ischemia and reperfusion (172-174). Kristian et al. report
mitochondria energized with either electron transport complex I or complex II substrates within
an acidic environment promote permeability transition pore opening (175). MPTP opening
increases the permeability of both inner and outer mitochondrial membranes. Because of MPTP
opening, solutes with a molecular mass of up to 1,500 Da non-selectively diffuse across the
mitochondrial inner membrane, leading to mitochondrial depolarization, uncoupling of
OXPHOS, and large amplitude swelling, leading to ATP depletion and cell death (174). The
effectiveness of mPTP inhibitors to protect the myocardium has not been observed in clinical
trials of acute myocardial infarction (176). However, neuronal cyclophilin D represents a
promising therapeutic target for Alzheimer’s disease (177). The development of nopeptidic small
molecule inhibitors of cyclophilin D could be a promising approach for cardiac arrest as our
study demonstrates a markedly increased susceptibility to MPTP opening within brain
mitochondria. This occurs during the initial period of ischemia due to CA and persists
throughout the course of CPR, including resuscitation and ROSC. In contrast, the susceptibility
of cardiac MPTP opening increases during ROSC. Therefore, brain MPTP susceptibility during
ischemia is different than in heart (178). Briston et al. reports complex I-driven respiration is
reduced after MPTP opening (179). Cardiac mitochondria are more resistant to damage during
ischemia. However, increased susceptibility to MPTP opening occurred during ROSC, likely as a
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result of calcium overload associated with reperfusion (180, 181). Therefore, reperfusion injury
affects heart mitochondria even after short durations of ischemia.
A complex I targeted therapeutic could also potentially ameliorate brain mitochondrial
dysfunction after cardiac arrest. Preservation of complex I activity could potentially provide
better clinical outcomes of survival with good neurological function (currently only 8.2%) and
survival to hospital discharge (currently 10.4%) (1). Further research is necessary regarding
mechanism among cardiac arrest victims. In a middle cerebral artery occlusion (MCAO) rat
model, decreased activity of Complex I, III, and IV after ischemia/reperfusion injury contributed
to decreased mitochondrial function, which was restored with a low-dose of methylene blue
(MB) (182). The neuroprotective role of MB in cerebral ischemia has been suggested to be
caused by increased mitophagy and maintenance of mitochondrial membrane potential (182).
Therapeutic Hypothermia is a standard intervention to improve outcomes following
cardiac arrest and cardiopulmonary resuscitation. Although therapeutic hypothermia can preserve
energy stores, current work also suggests that reactive oxygen species production is also
decreased (183, 184). This is plausible, since hypothermia decreases rates of electron transport.
Transient, partial blockade of electron transport during early reperfusion protects the heart (125,
185, 186). Hypothermia slows electron transport and reactive oxygen species generation in the
intact heart with a similar profile to that of blockade of electron transport (187). Thus, there is a
premise for protection of the brain and heart following cardiac arrest by therapeutic hypothermia
(WIN55 via CB1).
Complex I preservation would mitigate lowered levels of ATP, dramatic shifts in calcium
concentration and cell swelling. Our study demonstrates the brain is most reliant on
mitochondrial bioenergetics (188). It takes less ischemia/reperfusion to cause dysfunction in the
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brain compared to the heart. Reperfusion of ischemic brain will lead to massive generation of
free radicals such as ROS and activation of several signaling pathways (9). Our findings suggest
that CPR is able to preserve heart mitochondrial function and viability longer than that of brain
during ongoing global ischemia despite low blood flow and oxygen delivery. A metabolic phase
of cardiac arrest (188) occurs earlier than reported previously. Therefore, preservation of brain
complex I activity during CA will likely continue to emerge as a critical therapeutic target.
WIN55 could be a pharmacologic tool as it has been shown to decrease brain injury reducing
both delayed cell death and glial damage (38).
CONCLUSIONS
Brain mitochondria are more sensitive to global ischemia compared to heart
mitochondria. Additionally, complex I is the most sensitive ETC complex to ischemic injury and
its activity determines rate of OXPHOS following CA and resuscitation. Preservation of brain
mitochondrial activity and function during CA may enhance outcomes and recovery. Future
work is needed to improve current clinical resuscitation success rates by addressing an early
therapeutic target preserving complex I activity during CA.
LIMITATIONS
Our generalized use of brain and heart within this dissertation are the cerebrum and
whole heart, which is a limitation within the current study. Future studies are needed to address
the following: visualization of structural damage using electron microscopy, measurement of
reactive oxygen species production, measurement of pro-inflammatory mediators and the use of
interventions to enhance complex I activity to determine beneficial effects. Analysis of
mitochondria with a treatment group of WIN55 would further enhance the mechanism of this
pharmacologic tool.
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CHAPTER 4: Quantitative mass spectrometric analysis of cardiac whole tissue lysate
proteome changes from our rat cardiac arrest and cardiopulmonary resuscitation model
RATIONALE
For aerobic cells ischemia is a critical change in the oxygen demand to delivery ratio
(189). CA is characterized by severe and generalized ischemia that persists during resuscitation
efforts and reverses only after ROSC (2). Ischemia causes reperfusion injury. In general,
reperfusion injury is proportional to the magnitude of the preceding period of ischemia. All
tissues can withstand variably short periods of ischemia that do not produce detectable functional
deficits or evidence of injury. However, once a critical duration of ischemia is exceeded, which
varies by cell type and organ, cell injury and/or death ensues (190). Within the usual timeframe
of CA and resuscitation, ischemic injury is most severe in organs with high metabolic demands,
such as the brain and heart (2).
Studies have shown that S100A8/A9 levels positively correlate with risk of acute
myocardial infarction (191, 192). Additionally, site-specific measurements of S100A8/A9 in
patients with acute coronary syndrome demonstrate that S100A8/A9 is markedly more elevated
at the site of coronary occlusion compared to systemic circulation (193). Further support of this
finding, immunostaining, reveals S100A8/A9 is specifically expressed in neutrophils and
macrophages infiltrating the myocardium post-infarction (192). Together, these studies
demonstrate S100A8/A9 is a major player in local inflammation caused by acute cardiovascular
events.
We hypothesize that S100A8/A9 expression increases within heart whole tissue lysate
after CA and CPR. The purpose of this study was to measure proteome changes following CA
using quantitative mass spectrometric analysis.
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RESULTS
Quantification of total protein concentration of supernatant was determined by a BCA™
Protein Assay (Figure 31). 4,997 proteins (Sham 3) were quantitatively identified across 3
groups of 11 samples using one TMT10plex Isobaric Label Reagent Set plus TMT11-131C
Label Reagent. 239 of the 4,997 proteins identified to be differentially expressed (fold change
>=1.25, p<0.05, n=3 or 4) upon CPR compared to Sham+Norm (Figure 32). 104 proteins
changed by at least 25% highlighted in purple (fold change >=1.25, p<0.05). Housekeeping
proteins are not changed. Another volcano plot of the 171 proteins changed <0.75 and >1.25 was
compared between CPR and Sham+Norm (Figure 33).
Four proteins that were most significant were Fibrinogen gamma chain precursor
(functions in hemostasis as one primary component of blood clots and functions during the early
stages of wound repair to guide cell migration during re-epithelialization) (194), Parvalbumin
alpha (in muscle it is thought to be involved in relaxation after contraction) (195), G-protein
coupled receptor (involved in cell recognition and communication processes) and Transketolaselike protein 2 isoform X1(protein has several cofactor biding sites including calcium binding)
(196). These four proteins with the greatest change in expression are noted, however, we focused
on S100A8 and S100A9 due to Li et al. connecting S100A8/A9 signaling with mitochondrial
complex I dysfunction and cardiomyocyte death in response to myocardial ischemia reperfusion
injury (132).
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Figure 31. Supernatant BCA Assay. Mean ± SD, One-way ANOVA, Tukey Post-hoc p> 0.05
vs Norm N=3 (Norm) or 4 (Sham and CPR). Equal protein loading allows for comparison of
TMT tags. My contribution (a) design of the experiments (c) Re-analysis of the data provided by
Poochon Scientific.
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Figure 32. Volcano Plot 4,997 Proteins Identified by Poochon Scientific. My contribution (a)
design of the experiments (c) Re-analysis of the data provided by Poochon Scientific.
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Figure 33. Volcano Plot CPR/Norm+Sham Ratio <0.75 and >1.25-171 Proteins Identified.
Accession Numbers 61098186-Fibrinogen gamma chain precursor [Rattus norvegicus],
11968064-Parvalbumin alpha [Rattus norvegicus], 60389876- G-protein coupled receptor and
564388869- Transketolase-like protein 2 isoform X1 [Rattus norvegicus]. Pink are S100A8 and
S100A9[Rattus norvegicus]. My contribution (a) design of the experiments (c) Re-analysis of the
data provided by Poochon Scientific.
Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes
and biological pathways, was used to map pathways from the 4,997 proteins identified by
Poochon Scientific (3,195 Kegg were able to be converted from the 4,997 NCBI). Biological
pathways such as oxidative phosphorylation (Figure 34), complement and coagulation cascades
(Figure 35), toll-like receptor signaling (Figure 36) and chemokine signaling were mapped
(Figure 37). The complement and coagulation cascade was identified to have multiple proteins
expressed after CA and CPR (64 Kegg were able to be converted from the 104 proteins >1.25)
(Figure 38). Genes highlighted in red indicate presence.
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Figure 34. 3,195 converted Kegg proteins rno00190 Oxidative phosphorylation-Rattus
norvegicus (rat) (81). Red indicates gene presence. My contribution (a) design of the
experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.
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Figure 35. 3,195 converted Kegg proteins rno04610 Complement and coagulation cascadesRattus norvegicus (rat) (36). Red indicates gene presence. (a) design of the experiments (c) Kegg
pathway analysis of data provided by Poochon Scientific.
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Figure 36. 3,195 converted Kegg proteins rno04620 Toll-like receptor signaling pathwayRattus norvegicus (rat) (16). Red indicates gene presence. (a) design of the experiments (c) Kegg
pathway analysis of data provided by Poochon Scientific.
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Figure 37. 3,195 converted Kegg proteins rno04062 Chemokine signaling pathway- Rattus
norvegicus (rat) (37). Red indicates gene presence. (a) design of the experiments (c) Kegg
pathway analysis of data provided by Poochon Scientific.
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Figure 38. 64 converted Kegg proteins (CPR/Sham+Norm Ratio -log10 p>1.25 ) rno04610
Complement and coagulation cascades-Rattus norvegicus (rat) (13). Red indicates gene
presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon
Scientific.
A scatter plot for the CA and CPR data that was used to create the KEGG pathway in
Figure 38 was generated through multidimensional scaling. Similar GO terms are grouped closer
together in the plot based on similar semantics (Figure 39). Color of biological processes clusters
corresponds to the p-value input provided by Poochon Scientific. Biological processes that are
most enriched and clustered together are pathways involved with ischemia reperfusion injury.
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Figure 39. REVIGO gene ontology clustering of biological processes based on semantic
similarity. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon
Scientific.
DISCUSSION
CPR/Sham+Norm ratio DAVID 6.8 analysis showed S100A8/A9 expression increased
(CPR avg higher than Sham+Norm avg). Intracellular S100A8/A9 is best known for the ability
to regulate transendothelial migration of leukocytes (73, 197). Both are constitutively expressed
in neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated
upon the onset of trauma, infection, heat, stress and other inflammatory processes (69).
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Extracellular S100A8/A9 is a damage associated molecular pattern after being released from
damaged or activated cells, therefore increased expression seen in heart tissue lysates obtained at
ROSC is due to ischemia/reperfusion injury from CA.
Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial
IR procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart. Proteomic analysis
from Poochon Scientific was performed on heart tissue lysate collected at ROSC (no more than
30 minutes from VF). S100A8/A9 is critical for IR induced myocardial death, the sequelae of
adverse cardiac remodeling, and heart failure (132). The release of S100A8 and S100A9 can
induce C3/CFB complement activation and secretion of multiple cytokines in inflammatory cells
to sustain and exacerbate inflammation (69). Therefore, they control early stages of inflammation
for cardiac IR injury after CA. Inhibition of S100A8/A9 activity during CA could be a potential
therapeutic target.
CONCLUSIONS
S100A8 and S100A9 have promising potential as new biomarkers for cardiovascular
inflammation. Inhibition of S100A8/A9 activity during CA may enhance outcomes and recovery.
LIMITATIONS
Confirmation of proteomic analysis still needs to be done at the tissue level. If we have
tissue available after lipidomic analysis from a collaborator-a future study could include
immunoblot of the brain and heart for S100A8 and S100A9. Du et al. discovered global ischemia
did not alter immunoblot protein levels of S100A8 and S100A9 at 0, 30 and 60 min. In vivo
ischemia for 2hrs resulted in strong S100A8 and S100A9 overexpression (198). Li et al reported
serum S100A8/A9 levels were significantly increased 1 day after percutaneous coronary
intervention in patients with acute myocardial infarction(132). Therefore, future studies could
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look at expression of S100A8 and S100A9 peptides in brain and heart and protein levels in
plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of S100A8/A9
protein expression with a treatment group of WIN55 would further enhance the mechanism of
this pharmacologic tool.
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CHAPTER 5: Anti-Inflammatory activity of WIN55, 212-2, a non-selective cannabinoid
CB1/CB2 receptor agonist in cultured RAW264.7 macrophage cells
RATIONALE
Macrophages are innate immune cells that form the first line of defense against invading
pathogens (62). Under different pathophysiologic conditions, activated macrophages are capable
of differentiating into phenotypically different states, including the classically activated (M1) and
the alternatively activated (M2) (61). M1 macrophages are characterized by the production of
pro-inflammatory cytokines, such as IL1, IL6, IL12, TNFα and chemokines, involved in various
inflammatory processes (61). They are major producers of TNFα and are also highly responsive
to TNFα (62). TNFα is rapidly released after trauma, infection, or exposure to bacterial-derived
LPS and has been shown to be one of the most abundant early mediators in inflamed tissue (62).
TLR signals have an important role in regulating macrophage polarization. In particular,
the TLR4 ligand LPS promotes macrophage differentiation toward M1 phenotype (61). TNFα
has been shown to play a pivotal role in orchestrating the cytokine cascade in many
inflammatory diseases and because of this role as a “master-regulator” of inflammatory cytokine
production, it has been proposed as a therapeutic target for a number of diseases (62). IL6 is also
another pro-inflammatory cytokine secreted by monocytes and macrophages after engagement of
Toll-like receptors (TLRs) that promotes inflammatory events (66, 199).
Hao et al. reported oxLDL-induced TNFα expression and ROS generation in RAW 264.7
mouse macrophages is considerably reduced by the synthetic cannabinoid WIN55. Reduced
TNFα expression and ROS production is mainly via the CB2 receptor, and partially linked with
the CB1 receptor. MAPK and NF-kappa β are inhibited by WIN55 activated CB1/CB2 receptor
signaling, suggesting their involvement in the attenuation of TNFα expression and ROS
generation (200). Therefore, we hypothesize that pre-treatment with WIN55 will have anti97

inflammatory effects against LPS induced pro-inflammatory mediators TNFα, IL6 and IL1β. The
purpose of this study was to measure LPS induced TNFα, IL6 and IL1β protein expression with
and without pre-treatment of WIN55 in mouse RAW 264.7 macrophages.
RESULTS
TNFα, IL6 and IL1β were all increased following LPS stimulation. Pre-treatment with
WIN55 decreased TNF-α (9,206±847 (SD) pg/mL) compared to 6hrs LPS (15,694±2,285
p<0.05) (Figure 40). Pre-treatment with WIN55 also decreased IL6 (7,136±1,238) and IL-1β
(89±21) compared to 24hrs LPS (10,318±2,092 and 207±26 p<0.05) (Figure 41
and Figure 42).
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Figure 40. Pre-treatment with WIN55 decreased TNFα compared to 6hrs LPS Mean ± SD,
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=3 in each group.
My contribution (a) design of the experiments (b) execution of experimental procedure (c)
Analysis of the data.
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Figure 41. Pre-treatment with WIN55 decreased IL6 compared to 24hrs LPS Mean ± SD,
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=6 in each group.
My contribution (a) design of the experiments (b) execution of experimental procedure (c)
Analysis of the data.
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Figure 42. Pre-treatment with WIN55 decreased IL1β compared to 24hrs LPS Mean ± SD,
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=6 in each group.
My contribution (a) design of the experiments (b) execution of experimental procedure (c)
Analysis of the data.
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DISCUSSION
LPS is a ligand for TLR 4. It is an endotoxin from the walls of Gram-negative bacteria
and is a potent stimulator of inflammatory cytokines in macrophages (201). The initial acute
innate immune response to LPS primes the adaptive immune system against further infection
(202). Macrophages are the major players in both innate and adaptive inflammatory responses.
For this reason, WIN55 was examined for its effect on the expression of TNFα, IL6 and IL1β
protein in mouse RAW 264.7 macrophage cells stimulated with LPS. Our macrophage cell
culture model indicates that WIN55 inhibited LPS stimulated proinflammatory mediators.
CONCLUSION
WIN55 inhibited LPS induced expression of pro-inflammatory cytokines.
LIMITATIONS
Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vitro.
There are two different antagonists of CB2 (SR144528 (114) and AM630 (200)) that can be
tested to determine if administration blocks the effect of WIN55. Antagonists of CB1 such as
SR141716A and AM251 also need to be tested to determine if administration blocks the effect of
WIN55. Further studies are also needed using more specific CB2 receptor agonists such as
HU308 or JWH-133 (200). Treatment with recombinant S100A8 proteins should also be
determined. RAW264.7 macrophage cells should be treated with WIN55 (5 μM) (142) for 2 h,
then treated with S100A8 for 6hrs and 24 hrs. S100A8 acts not only as a chemoattractant to
macrophages but also as a proinflammatory factor (203). Inhibitors of S100A8 and/or S100A9
should also be tested in vitro. PPARγ expression should also be determined as WIN55 induced
PPARγ expression was partially attenuated by AM630 in BEL-7402 cells (204). The effects of
WIN55 should also be tested to determine if they are attenuated by PPARγ antaonist GW9662
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(204). PPAR-γ agonists significantly reduced adipose S100A8 mRNA level and plasma
S100A8/A9 complex concentrations in obese diabetic mice and human subjects (203). After
these effects are determined in RAW264.7 macrophage cells confirmation studies can be
conducted in human THP-1 cell lines.
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CHAPTER 6: One mechanism of anti-inflammatory activity of cannabinoid agonist
WIN55, 212-2 on outcomes of CPR is binding cannabinoid receptor 2 (CB2)

RATIONALE
In non-traumatic CA, common causes are ventricular fibrillation cardiac arrest (VFCA)
and asphyxial cardiac arrest (ACA) (205). Recent data from several large population cohorts,
covering over 40,000 patients, demonstrate proportions of initial ventricular
tachycardia/ventricular fibrillation in the range of 20-25% (13). The 2016 weighted national
estimate of emergency department visits with a principal diagnosis of either CA or ventricular
fibrillation/flutter was 183,629 patients among the National Emergency Department Sample (1).
For this reason, our physiologically relevant VF model developed in 1988 has been used in
approximately 70 peer-reviewed publications examining resuscitation aspects including: its
physiology and pathophysiology, determinants of resuscitability, pharmacologic interventions,
and effects of cell therapies (206). Once we confirmed in vitro WIN55 inhibited LPS induced
expression of pro-inflammatory cytokines within mouse RAW 264.7 macrophage cells we then
explored our experimental in vivo CA/CPR (145, 162, 163) rat model.
The Weil Institute has published that infusion of WIN55 decreases body temperature
from 37 to 34oC within 4 hours after infusion (114, 207). All animals that received WIN55
survive for more than 72 hours with minimal neurological deficits. Post-resuscitation myocardial
function is significantly better than control. We therefore demonstrate the feasibility that
therapeutic hypothermia could be induced pharmacologically in settings of CPR without
compromising outcomes (207). We further demonstrate that hypothermia effects of WIN55 are
completely abolished by selective CB1 receptor antagonist SR141716A (114, 208).
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The role of endocannabinoids (eCBs) in the cardiovascular system is paradoxical because
both positive and negative effects are observed, particularly in conditions of cardiovascular
dysfunction (209). We hypothesize that CA will increase plasma concentrations of TNFα, IL6
and IL10. Therefore, plasma cytokine levels will be elevated after resuscitation. Intramuscular
(IM) administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after
ROSC will prohibit the release of inflammatory mediators caused by CA via the CB2 receptor.
The purpose of this study was to measure hemodynamics (electrocardiogram, aortic and right
atrial pressures, blood temperature, and ETCO2 values), myocardial function (EF, CO, and MPI)
and plasma protein concentrations following CA with and without administration of SR141716A
before VF+CPR followed by infusion of WIN55 5 min after ROSC.
RESULTS
Our most recent WIN55 publication and our current studies administered WIN55 5
minutes after ROSC. Blood temperature in WIN55 + Hypothermia decreased progressively from
36.8°C ± 0.2°C to 35.1°C ± 0.5°C during the first hour of infusion and reached 33.3°C ± 0.3°C at
4 hours after infusion (145). Duration of reduced blood temperatures did not have a significant
difference between WIN55 + Hypothermia and Hypothermia, which had a similar rate for
temperature drop. Due to the use of a heated surgical board, there was no significant reduction in
blood temperature in animals with WIN55 + Normothermia which was similar to Normothermia.
There was no significant reduction in blood temperature in animals pretreated with SR141716A
(Figure 43) (114).

105

Blood Temperature

Temperature (°C)

39

2% Tween
SR141716A + WIN55

38
37
36
35
34

B

e
lin
e
as
R

O

SC

r
1h
R

O

SC

rs
2h
R

O

SC

rs
3h
R

O

SC

rs
4h

Figure 43. Blood temperature was not different between groups. Mean ± SD, Unpaired t test,
p>0.05 vs 2% Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the
experiments (b) execution of experimental procedure (c) Analysis of the data.
MAP and HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased
significantly compared with Normothermia at ROSC 1hr, 2hrs, 3hrs, and 4hrs (Figure 44 and
Figure 45), while ETCO2 in WIN55 + Hypothermia increased significantly compared with
Normothermia (Figure 46) (145). HR in SR141716A+WIN55 decreased significantly compared
to 2% Tween 80 at ROSC 2hrs and 3hrs (Figure 47) while ETCO2 increased significantly
compared with 2% Tween 80 at ROSC 1hr and 4hrs (Figure 48). Administration of
SR141716A+WIN55 followed similar hemodynamic changes from previously published results
(145).
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Figure 44. MAP in WIN55 + Hypothermia and WIN55 + Normothermia decreased
significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Posthoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a)
design of the experiments (c) Re-analysis of the data.
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Figure 45. HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased
significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Posthoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a)
design of the experiments (c) Re-analysis of the data.
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Figure 46. ETCO2 in WIN55 + Hypothermia increased significantly compared with
Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01
***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments
(c) Re-analysis of the data.
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Figure 47. HR in SR141716A+WIN55 decreased significantly compared to 2% Tween 80 at
ROSC 2hrs and 3hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2%
Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b)
execution of experimental procedure (c) Analysis of the data.
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Figure 48. ETCO2 increased significantly compared with 2% Tween 80 at ROSC 1hr and
4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3,
SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
There was a significant improvement in myocardial function as measured by CO, EF, and
MPI, in animals treated with WIN55 + Hypothermia beginning at 1 hour after start of infusion.
WIN55 + Hypothermia significantly improved at ROSC 4hrs compared with Physical
Hypothermia (Figure 49, Figure 50 and Figure 51) (145). MPI in SR141716A+WIN55
increased significantly compared with 2% Tween 80 at ROSC 4hrs (Figure 52).
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Figure 49. Significant improvement in myocardial function as measured by CO. Mean ±
SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia
N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
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Figure 50. Significant improvement in myocardial function as measured by EF. Mean ± SD,
One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in
each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
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Figure 51. Significant improvement in myocardial function as measured by MPI. Mean ±
SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia
N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
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Figure 52. MPI in SR141716A+WIN55 increased significantly compared with 2% Tween
80 at ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween
N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
TNFα, IL6, cardiac troponin I and IL10 expression in plasma were all increased
following CA/CPR (Figure 53, Figure 54, Figure 55 and Figure 56). IM Administration of
SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide) before VF 6 min +
CPR 8 min, defibrillation and ROSC followed by infusion) of WIN55 (1 mg/kg/h) administered
by continuous intravenous infusion with a syringe pump (Genie Touch; Kent Scientific
Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114) decreased expression in plasma TNFα,
IL6, and IL10 at ROSC 4hrs (Figure 53, Figure 54 and Figure 56). Cardiac troponin I and
S100A8 protein expression was not different between groups (Figure 55 and Figure 57).
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Figure 53. Plasma TNFα. IM Administration of SR141716A before VF+CPR followed by
infusion of WIN55 5 min after ROSC significantly decreased TNFα plasma protein expression at
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3,
SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
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Figure 54. Plasma IL6. IM Administration of SR141716A before VF+CPR followed by
infusion of WIN55 5 min after ROSC significantly decreased IL6 plasma protein expression at
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3,
SR141716A+WIN55 N=3. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
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Figure 55. Plasma Troponin I. IM Administration of SR141716A before VF+CPR followed by
infusion of WIN55 5 min after ROSC had no effect on cardiac troponin I plasma protein
expression at ROSC 4hrs. Mean ± SD, Unpaired t test, p>0.05 vs %Tween N=3,
SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
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Figure 56. Plasma IL10. IM Administration of SR141716A before VF+CPR followed by
infusion of WIN55 5 min after ROSC decreased IL10 plasma protein expression at ROSC 4hrs.
Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs %Tween N=3,
SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
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Figure 57. Plasma S100A8. IM Administration of SR141716A before VF+CPR followed by
infusion of WIN55 5 min after ROSC had no effect on S100A8 plasma protein expression at
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs %Tween N=3,
SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of
experimental procedure (c) Analysis of the data.
DISCUSSION
In the cardiovascular system, CB2 is present in various cell types (97). Therefore, IM
Administration of SR141716A (CB1 antagonist) before VF+CPR followed by infusion of WIN55
(CB1 and CB2 agonist) 5 min after ROSC was used as a treatment group to determine CB2
agonist response to CA/CPR. HR decreased significantly at ROSC 2hrs and 3hrs while ETCO2
increased significantly at ROSC 1hr through 4hrs with treatment. MPI also increased
significantly at ROSC 4hrs. Our experimental CA/CPR (145, 162, 163) model indicates that
TNFα, IL6, and IL10 plasma protein expression is decreased at ROSC 4hrs with
SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression did not
change between groups. This could be due to the timing of plasma collection (ROSC 4hrs).
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Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial IR
procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart (132).
CONCLUSION
TNFα, IL6, and IL10 plasma protein expression decreased at ROSC 4hrs with
SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression does not
change.
LIMITATIONS
Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vivo.
There are two different antagonists of CB2 (SR144528(114) and AM630(200)) that can be tested
to determine if administration blocks the anti-inflammatory effect of WIN55. Antagonists of CB1
such as AM251 also need to be tested to determine if administration blocks the antiinflammatory effect of WIN55. Further studies are also needed using more specific CB2 receptor
agonists such as HU308 or JWH-133(200).
If we have tissue available after lipidomic analysis from a collaborator-a future study
could include immunoblot of the brain and heart for S100A8 and S100A9. Therefore, future
studies could look at expression of S100A8 and S100A9 peptides in brain and heart and protein
levels in plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of
S100A8/A9 protein expression with a treatment group of WIN55 would further enhance the
mechanism of this pharmacologic tool. Inhibitors of S100A8 and/or S100A9 should also be
tested in vivo. The effects of WIN55 should also be tested to determine if they are attenuated by
PPARγ antagonist GW9662 (204).
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CHAPTER 7: Summary and Future Direction

Accumulating evidence indicates that synthetic or endogenous cannabinoids protect
against central nervous system injury by factors including ischemia and reperfusion (200). Brain
CB2 receptors are highly inducible; thus, under some pathological conditions (inflammation),
CB2 expression is quickly enhanced (109). Di Filippo et al. demonstrate that treatment with the
synthetic nonselective CB1/CB2 receptor agonist WIN55 significantly reduces the extent of
myocardial infarct in mice suffering from myocardial IR injury; cardio protection is
accompanied by lower myeloperoxidase activity and IL-1β and CXC chemokine ligand levels in
injured tissue. This cardioprotective effect is almost abolished by the selective CB2 antagonist
AM630, but it is not affected by the selective CB1 antagonist AM251 (200) (Fig 42). Although
several rodent models have shown promising actions of cannabinoids on the cardiovascular
system, we are a long way from seeing these compounds on the market (84). Selective CB1
receptor antagonists were withdrawn from the market because of increased risk of depression
(200).
The effects of WIN55 were investigated initially in our rat model of CA and CPR.
WIN55 was selected based on the following reasons: 1) the described hypothermia effect of CB1
agonist is convincing and well documented, 2) it is highly selective for cannabinoid receptors
and interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in
thermoregulatory areas of the central nervous system and therefore decreases body temperature
via a central mechanism (119), 4) It has been shown to be neuroprotective (120) and 5) It has
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been demonstrated in both mice and rats that the CB2 receptor activation effects of WIN55 have
significant anti-inflammatory effects (121-123). Our experimental CA/CPR (145, 162, 163)
model indicates that local S100A8/A9 protein expression is increased within heart whole tissue
lysates after CA and CPR. We then confirmed WIN55 inhibited LPS induced expression of proinflammatory cytokines in mouse RAW 264.7 macrophage cells. In vivo TNFα, IL6, and IL10
plasma protein expression decreased at ROSC 4hrs with SR141716A+WIN55 treatment. Li et al
recently report S100A8/A9 causes mitochondrial dysfunction via suppression of TLR4/ERK
subsequent to mitochondrial complex I inhibition. S100A8/A9 is significantly upregulated
during the early reperfusion stage (132). Mitochondria have emerged as central organelles that
integrate metabolism and inflammatory responses (79). Therefore, future studies are necessary to
determine if WIN55 could be a potential therapeutic to mitigate brain and heart damage after CA
and CPR by blocking S100A8/A9 expression. We have determined brain mitochondria are more
sensitive to global ischemia compared to heart mitochondria. Additionally, complex I is the most
sensitive ETC complex to ischemic injury and its activity determines rate of OXPHOS following
CA and RES. Preservation of brain mitochondrial activity and function during CA by inhibition
of S100A8/A9 may enhance outcomes and recovery. For this reason, WIN55 could be a
pharmacologic tool that preserves complex I activity during CA.
The exact mechanism by which CB2 activation leads to anti-inflammatory effects and
possible S100A8/A9 inhibition needs further investigation with macrophage in vitro studies and
our experimental CA/CPR (145, 162, 163) model survival studies (Fig 43). Li et al report serum
S100A8/A9 levels 1 day post-percutaneous coronary intervention was significantly greater than
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other points (132). We could then look at brain and heart mitochondria, local S100A8 histology
and protein expression within the brain and heart along with systemic TNFα, IL6, IL10, cardiac
troponin, and S100A8 plasma protein expression 24hrs and 48hrs after ROSC.

(SR141716A)

SR144528

HU308
or
JWH-133

Figure 58. Pathways of cannabinoid receptor-mediated protection against Ischemia
reperfusion injury. Adapted from (82)
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Figure 59. Potential WIN55 inhibition of S100A8 and S100A9. Upon forming a heterodimer,
S100A8/A9 is able to exert both intracellular and extracellular effects. Intracellularly,
S100A8/A9 serves as a regulator of leukocyte transendothelial migration by promoting
microtubule polymerization. It also promotes the downregulation of mitochondrial electron
transport chain complex I and ATP production. Extracellularly, S100A8/A9 acts as a damageassociated molecular pattern (DAMP) by binding to TLR4 receptors on phagocytes and
triggering the production of inflammatory cytokines.
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VITA
Jennifer Leigh Bradley was born on December 5, 1983 in Charleston, West Virginia. She
graduated from Saint Albans High School, Saint Albans, West Virginia in 2002. In May 2006,
she received her Bachelor of Arts in Biology from Berea College, Berea, Kentucky. In December
2016, she received her Masters of Science in Microbiology and Immunology with a
concentration in Molecular Biology and Genetics from Virginia Commonwealth University,
Richmond, Virginia. In the fall of 2017, she continued her graduate career at Virginia
Commonwealth University, School of Medicine, Department of Microbiology and Immunology
with a concentration in Molecular Biology and Genetics.
Education
Virginia Commonwealth University
Doctor of Philosophy in Microbiology and Immunology
Concentration: Molecular Biology and Genetics
Graduation Spring 2021 Current GPA 3.673
Virginia Commonwealth University
Master of Science in Microbiology and Immunology
Concentration: Molecular Biology and Genetics
Berea College
Bachelors of Arts in Biology

Richmond, Virginia
2016

Berea, Kentucky
2006

Research Experience
Virginia Commonwealth University, Richmond, VA
Laboratory and Research Manager
Weil Institute of Emergency and Critical Care Research at VCU
Director: Dr. Wanchun Tang
Deputy Directors: Dr. Mary Ann Peberdy and Dr. Joseph Ornato
Research Focus: Cardiopulmonary Resuscitation
•

Richmond, Virginia
2017-present

June 2016 – Present

Research Management: I have knowledge of the University research rules and policies
and the skills necessary for program development and implementation, including
developing project budgets and providing guidance in project management. I help the
directors with development of plans for studies that include budget, personnel, space,
supplies and equipment. I also have the ability to conduct tests, draw conclusions, and
record and document findings including statistical analysis (JMP and Prism). I synthesize
research data and draft research grant applications and publishable documents. I also
maintain the research website and work with the directors to coordinate the Wolf Creek
Conference.
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Clinical Research Experience: I possess knowledge and experience with human research
subject protection (IRB/WIRB) and HIPAA, including CITI Biomedical, Export
Controls, Clinical Research Coordinator, Faculty, Staff, and Students, and GCP
certification. I also attended the SOM New Coordinator Training-Nuts and Bolts in
August 2016.
Bench Research: I directly supervise research staff by providing training, direction,
guidance, and evaluation of operating instruments. This includes a total of 6 visiting
scholars each year. I was able to perform the Weil Institute’s small animal cardiac arrest
model and maintained complex specialized laboratory instruments this past summer. My
responsibilities include delegation of project workloads, providing guidance for project
management and adhering to University regulations for inspection.
Animal Research: I monitor the care of research animals and act as a liaison with the
IACUC office to ensure that all procedures are in compliance with IACUC and
University regulations. This includes IACUC submission, husbandry management,
animal ordering, controlled substances, and all inspections. I am also a member of the
ACUPAC for IACUC.

Virginia Commonwealth University, Richmond, VA
February 2014 – June 2016
Laboratory and Research Specialist II- Laboratory Manager
Department of Pediatrics
Principal Investigators: Dr. Bruce Rubin & Dr. Henry Rozycki
Research Focus: Aerosol therapy, Airway clearance for lung disease and Type I Alveolar
Epithelial Cells
•

Laboratory Management: I provided support and assistance to the Chairman of Pediatrics
with the oversight of basic, translational, and clinical research efforts conducted within
his laboratory, which required knowledge of the University research rules and policies. I
also acted as a liaison with the Associate Administrative Director of Pediatric Research
for all budgetary processes and monitoring of the Department Chair’s expenditures. I
developed plans and trials for studies that included budget, personnel, space, supplies,
and equipment. I also generated budgets for Co-Investigators and Sub-Investigators with
other departments. I managed the onboarding of postdoctoral fellows and students for the
laboratory and handled travel arrangements and reimbursements for conferences for the
PI and lab members. I also scheduled international teleconference calls and planned
accordingly for grant and abstract deadlines. My role required excellent customer service
skills; the ability to effectively communicate and to work with individuals from diverse
backgrounds and to work in a team environment. I was skilled in program development
and implementation and established study time lines and communicated with sponsors for
study updates. My role required me to determine priorities and work in a fast-paced,
deadline driven environment. I developed and maintained systematic ways for filing and
archiving all study related documents and supervised and/or performed data processing
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and data analysis. I oversaw quality assurance of data, assisted with the development of
collection methods, and created and revised study materials, forms, and manuals as
needed. I prepared detailed reports for sponsors of experiments, progress reports,
informed consent, etc. This required me to review scientific journals, abstracts, and other
related literature for information concerning experimental procedures and supplemental
support. I also performed troubleshooting on laboratory equipment and acted as the
primary contact for vendors, compliance officers, and sponsoring agencies. I worked with
post-award monitoring grant expenditures, ordering supplies (Pcard, EVA, Banner and
supply center) and organized lab meetings to maintain dialog among co-investigators
regarding progress. I maintained the research website, trained students, and conducted
laboratory tours for elementary to high school-aged children.
Statistical Analysis: I supervised and/or performed data processing, coordinated data
analysis, and oversaw quality assurance of data. I became proficient in JMP and
Microsoft Excel.
Clinical Research Experience: I maintained the Rubin laboratory webpage, patient
registry, and airway sample bank and ensured all were in compliance with IRB/WIRB
and University regulations. I consented/enrolled research subjects, conducted study
visits, processed clinical samples, and maintained REDCap databases. My duties required
experience in clinical trial management, international registries, patient enrollment,
sputum collection and processing. I possessed knowledge and experience with human
research subject protection (IRB/WIRB) and HIPAA, including CITI Biomedical, Export
Controls, Clinical Research Coordinator, Faculty, Staff, and Students, and GCP
certification. I also trained in CERNER, OnCore, MERCK ICH GCP, Adverse
Experience Reporting, and InForm v4.6 for sponsored clinical trials.
Bench Research: I directly supervised research staff and provided training, direction,
guidance, and evaluation of operating instruments. I operated and maintained complex
specialized laboratory instruments and was responsible for delegating project workloads
and providing guidance in project management. I performed Sputum Biophysical
Analysis (rheology, sputum hydration, and cough clearance), ELLA/ELISAs, RT-PCR,
DNA/RNA isolation, tissue culture models: submerged and air-liquid interface of NHBE
and Type I Alveolar Epithelial Cells, western blots, FACS, confocal, and
immunohistochemistry. I possessed the ability to conduct tests, draw conclusions,
record, and document findings.
Animal Research: I monitored the care of research animals and acted as a liaison with the
IACUC office to ensure that all procedures were in compliance with IACUC and
University regulations. This included IACUC submission, husbandry management,
animal ordering, controlled substances, and all inspections. I also taught rodent nonsurvival surgery techniques such as tracheostomy and isolation of lungs after
bronchoalveolar lavage, mouse breeding and colony management, and sputum
mucociliary transportability analysis on an upper frog palate.
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Virginia Commonwealth University, Richmond, VA
March 2013 – February 2014
Laboratory and Research Specialist II- Senior Technician
Department of Pediatrics
Principal Investigators: Dr. Bruce Rubin & Dr. Henry Rozycki
Research Focus: Aerosol therapy, Airway clearance for lung disease and Type I Alveolar
Epithelial Cells
• Laboratory Management: I reviewed scientific journals, abstracts, and other related
literature for information concerning experimental procedures and supplemental support.
I performed troubleshooting on laboratory equipment and assisted the research manager
with monitoring grant expenditures, ordering supplies (Pcard, EVA, Banner and supply
center) and organizing lab meetings. I also helped maintain the Rubin lab website,
trained students, and conducted laboratory tours for elementary to high school-aged
children.
• Statistical Analysis: I became proficient in JMP and Microsoft Excel, which helped with
presentation of data during weekly laboratory meetings and preparation of industry
reports.
• Clinical Research Experience: I consented/enrolled research subjects, conducted study
visits, processed clinical samples, and maintained REDCap databases.
• Bench Research: I performed Sputum Biophysical Analysis (rheology, sputum hydration,
and cough clearance), ELLA/ELISAs, RT-PCR, DNA/RNA isolation, tissue culture
models: submerged and air-liquid interface of NHBE and Type I Alveolar Epithelial
Cells, western blots, FACS, confocal, and immunohistochemistry.
• Animal Research: I taught rodent non-survival surgery techniques such as tracheostomy
and isolation of lungs after bronchoalveolar lavage, mouse breeding and colony
management, and sputum mucociliary transportability analysis on an upper frog palate.
Virginia Commonwealth University, Richmond, VA
February 2012 – March 2013
Laboratory and Research Specialist I- Lab Manager
Department of Microbiology and Immunology
Principal Investigator: Dr. Daniel Conrad
Research Focus: Immunology, cancer biology, and immunotoxicology
• Laboratory Management: I facilitated the radiation safety inspections and all applicable
paperwork involved including monitoring of radioisotope levels and use and disposal of
hazardous waste. I also acted as the Chemical Hygiene Officer. I managed laboratory
post award grant reconciliation between the Microbiology and Immunology Office,
ordered supplies, maintained and performed troubleshooting on all laboratory equipment
and supervised graduate students/hourly workers.
• Bench Research: I observed and assisted with flow cytometry, western blotting, and real
time PCR. I also performed ELISAs and collected tissues and specimens for laboratory
analysis.
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Animal Research: I monitored the care of research animals and acted as a liaison with the
IACUC office to ensure that all procedures were in compliance with IACUC and
University regulations. I also managed the mouse breeding colony of a myriad of
knockout and transgenic strains. I conducted Flexivent procedures: non-survival surgery
to investigate the effects of the house dust mite on various transgenic mouse models.

Virginia Commonwealth University, Richmond, VA
July 2008 – February 2012
Laboratory and Research Specialist I- Laboratory Specialist
Department of Periodontics
Principal Investigator: Dr. Harvey Schenkein
Research Focus: Immunopathology of periodontal disease
• Bench Research: I developed and modified protocols and carried out research
independently- including tissue culture to isolate human blood cells for culture. I ensured
sterility, maintained and grew cell lines, and maintained anaerobic bacterial cultures
without contamination. I also performed standard immunological assays such as
separation of immune cells, prepared solutions, sterilized reagents and apparatus, and
disposed of radioisotope equipment.
• Animal Research: I gained extensive knowledge of breeding techniques and pregnant
mouse/pup anatomy.
Office of Laboratory Services, South Charleston, WV
March 2007-July 2008
Microbiologist I
• Performed standardized bacteriologic and serologic examinations along with QC
procedures for the state public health laboratory.
• Carried out primary isolation techniques of microorganisms; prepared media, solutions,
and reagents.
• Operated laboratory equipment and/or scientific instrumentation for use in conducting
diagnostic procedures, which included sterilization of apparatus.
• Compiled and maintained records on the characteristics of the organisms identified.
• Performed bacterial identification from patient cultures.
• Operated gen probe (transcription-based amplification system).
• Serotyped salmonella, shigella, e. coli, and meningitis isolated cultures.
• Identified parasites using microscopy techniques on patient stool samples.
• Processed sputum cultures to isolate tuberculosis.
• Ensured proper immunohistochemistry-monoclonal antibody staining for the detection of
rabies virus.
• Examined animal cranial necropsy for the identification of rabies.

145

West Virginia State Police, South Charleston, WV
December 2006-March 2007
Evidence Technician I
Forensic Laboratory
• Provided for the custody of all evidence submitted by various law enforcement agencies
in West Virginia.
• Maintained detailed records and integrity of evidence according to established laws,
regulations, and standards.
Publications
Cheng C, Li H, Liang L, Jin T, Zhang G, Bradley JL, Peberdy MA, Ornato JP, Wijesinghe DS,
Tang W. Effects of ω-3 PUFA and ascorbic acid combination on post-resuscitation myocardial
function. Biomedicine and Pharmacotherapy. 2021;133:110970.
Xiao, Y., Contaifer, D., Huang, W., Yang, J., Hu, Z., Guo, Q., Bradley, JL, Peberdy, M.A.,
Ornato JP, Wijesinghe, D., and Tang, W. Cannabinoid Receptor Agonist WIN55m212-2 Adjusts
Lipid Metabolism in a Rat Model of Cardiac Arrest. Therapeutic Hypothermia and Temperature
Management. 2020; doi: 10.1089/ther.2019.0038
Ge, W., Zheng, G., Ji, X., He F., Hu, J., Bradley, JL, Moore C., Peberdy, MA, Ornato, JP,
Mangino MJ, and Tang, W. Effects of Polyethylene Glycol-20k on Coronary Perfusion Pressure
and Postresuscitation Myocardial and Cerebral Function in a Rat Model of Cardiac Arrest. J Am
Heart Assoc. 2020;9:e014232
Li H, Hua T, Wang W, Wu X, Miao C, Huang W, Xiao Y, Yang J, Bradley JL, Peberdy MA,
Ornato J, Dix TA, Beck T, Tang W. The Effects of Pharmacological Hypothermia Induced by
Neurotensin Receptor Agonist ABS 201 on Outcomes of CPR. Shock. 2019 May;51(5):667-673.
doi: 10.1097/SHK.0000000000001178.
Yang J, Xiao Y, Quan EY, Hu Z, Guo Q, Miao C, Bradley J, Peberdy MA, Ornato JP, and Tang
W. Effects of Polyethylene Glycol-20k on Postresuscitation Myocardial and Cerebral Function in
a Rat Model of Cardiopulmonary Resuscitation. Crit Care Med. 2018 Dec; 46(12):e1190-e1195
Wang W, Hua T, Li H, Wu X, Bradley J, Peberdy MA, Ornato JP, and Tang W. Decreased
cyclic adenosine monophosphate level and decreased downregulation of β1-adrenoceptor
expression in therapeutic hypothermia resuscitated myocardium are associated with improved
post-resuscitation myocardial function. J Am Heart Assoc. 2018 Mar 20;7(6):e006573
Lu X, Fries M, Ravindra N, Bradley J, Peberdy MA, Ornato JP, Zhu CQ and Tang W. The
Individual Role of Sarcolemmal and Mitochondrial KATP Channels Opening During
Cardiopulmonary Resuscitation in a Porcine Model Treated with Levosimendan. Heart Circ
2017; 1:017.
Sun P, Wang J, Zhao S, Yang Z, Tang Z, Ravindra N, Bradley J, Ornato JP, Peberdy MA, Tang
W. Improved Outcomes of Cardiopulmonary Resuscitation in Rats Treated with Vagus Nerve
Stimulation and its Potential Mechanism. Shock 2017 Aug 9. [epub ahead of print]
Miao C, Yang Z, Wen C, Yu T, Ravindra N, Bradley J, Peberdy MA, Ornato JP, and Tang W.
Nitroglycerin Improves Microcirculation During and After Cardiopulmonary Resuscitation in a
Porcine Model of Cardiac Arrest. Ann Cardiol Cardiovasc Dis. 2017.2(2):1011
146

Hua T, Wu X, Wang W, Li H, Bradley J, Peberdy MA, Ornato JP, Tang W. Micro-and Macro
Circulatory Changes During Sepsis and Septic Shock in a Rat Model. Shock 2017 Jul 20. [epub
ahead of print]
Rozycki HJ, Bradley J, KaramS. sRAGE is Elevated in the Lungs of Premature Infants
Receiving Mechanical Ventilation. Am J Perinatol. March 2017
Wang J, Wu X, Yan Z, Zhao S, QianJ, Yin L, Yu H, Gong P, Cahoon J, Bradley J, and Tang W.
Protective Effects of Progesterone on Neurological outcomes in a Rat Model of Cardiac Arrest.
Arch Emerg Med Crit Care December 2016 1 (3):1016
Schenkein H.A, Bradley JL and Purkall D.B. Anticardiolipin in Porphyromonas gingivalis
Antisera Causes Fetal Loss in Mice. Journal of Dental Research July 2013 92: 814-818
Conferences
Society of Critical Care Medicine Annual Congress 2020
Wolf Creek Conference 2017, 2019, 2021
American Thoracic Society International Conference 2013, 2014, 2015, and 2016
American Association for Respiratory Care Conference 2013
Grants and Scholarships
2020-VCU Staff Senate Integrity Award $500
2020-Graduate School Travel Grant $300
2020-MPG CPC Travel Award $1,500
2019-VCU Graduate School Hibbs/Waller Scholarship $1,000.
2019-Jennifer Bradley, Mentor: Dr. Wanchun Tang, Measurement of systemic inflammatory
response after administration of WIN55, 212-2. Zoll Foundation. $30,000.
2018-MBG CPC Travel Award $180
2018 Fall LabRoots Scholarship $2,000
2017-2017-B Love of Learning Award from Phi Kappa Phi $500
2015-Jennifer Bradley, Mentor: Dr. Bruce Rubin, Mature adipocytes from obese individuals
release IL-13, which increases inflammation and induces a goblet cell phenotype in normal
human bronchial epithelial (NHBE) cells at air-liquid interface (ALI). Children’s Hospital
Foundation Research Fund. $5,000.
Additional Training & Recognition
VCU Training
• Grace E Harris Leadership Institute 2020 class of the HIGHER Ground Women’s
Leadership Development Program
• Wright Center Grant Writing Course
• Multiple Manager Training courses from Human Resources
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Multiple Corporate Education Training courses (Leading Effective Teams, Maximizing
Productivity and Managing and Leading Change)
SOM New Clinical Research Coordinator Boot Camp
Records Management 101

Collaborative Institutional Training Initiative Course:
•
•
•
•
•

Faculty, Staff, and Students
Biomedical Responsible Conduct of Research
Good Clinical Practice
CITI Export Controls
Clinical Research Coordinator (CRC)

American Association for Laboratory Animal Science:
•
•
•
•
•
•
•
•
•
•
•
Other
•
•
•
•
•
•
•
•
•
•
•

Aseptic Technique for Rodent Survival Surgery
Introduction to Amphibians
Introduction to Ferrets
Introduction to Mice
Introduction to Rabbits
Introduction to Rats
Introduction to Swine
Mouse Breeding Colony Management
Post-procedure Care of Mice and Rats in Research Minimizing Pain and Distress
VCU Animal Research Facility Orientation Course
Working with the VCU IACUC for staff and students

Write Now Summer Session National Center for Faculty Development & Diversity 2020
Grantsmanship for Research Professionals 2020
RAMS Forum 2018, 2019, 2020
NCURA Sponsored Project Administration Workshop April and September 2019
Building Inclusive Communities June 2018
Bioinformatics 102 June 2018
Writing and Designing NIH Proposals Webinar February 2017
SBIR Webinar January 2017
NIH Grantsmanship Workshop January 2017
VCU Professional Development Certificate Program September 2016 to present
Virginia Grants Summit September 2016
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Dangerous Goods Shipping

Student spotlight for VCU Graduate School website Fall 2019:
https://graduate.vcu.edu/welcome/graduate-school-news/student-spotlights/student-spotlight--jennifer-bradley/
Member, Society of Critical Care Medicine 2018-present
Member, American Association for the Advancement of Science 2018
Member, The Honor Society of Phi Kappa Phi November 2014-present
Mentorship
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Summer 2020. Mentor Karen Lo. VCU Medical Student Volunteer.
Summer 2020. Mentor Matthew Olocco. VCU Medical Student Volunteer.
Summer 2020. Mentor Hunter Hewlett. VCU Medical Student Volunteer.
2019-2020. Mentor Chengli Su, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2019-2020. Mentor Yan Xiao, MD, PhD. Weil Institute of Emergency and Critical Care
Research Post-doctoral Scholar.
2019-2020. Mentor Guozhen Zhang, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2019-2020. Mentor Jin Tao, MD. Weil Institute of Emergency and Critical Care Research
Visiting Fellow.
2019-2020. Mentor Cheng Cheng, MD, PhD. Weil Institute of Emergency and Critical
Care Research Visiting Fellow.
2019-2020. Mentor Hui Li, MD. Weil Institute of Emergency and Critical Care Research
Visiting Fellow.
2019-2020. Mentor Lian Liang, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
Summer 2019. Mentor Iris Huang. High School Student Volunteer.
Summer 2019. Mentor Liuzhi Zhang. VCU Medical Student Volunteer.
Summer 2019. Mentor Lazar Jankovic. VCU Medical Student Volunteer.
Summer 2019. Mentor Helen Mai. VCU Undergraduate Student Volunteer.
Summer 2019. Mentor Esha Sharma. Godwin High School Student Volunteer Intern.
Summer 2019. Mentor Devi Veeramgari. Godwin High School Student Volunteer Intern.
Summer 2019. Mentor Aaron Yuan. Godwin High School Student Volunteer.
2018-2019. Mentor Fenglian He, MD, PhD. Weil Institute of Emergency and Critical
Care Research Visiting Fellow.
2018-2019. Mentor Juntao Hu, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
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2018-2019. Mentor Xianfei Ji, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2018-2019. Mentor Weiwei Ge, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2018-2019. Mentor Guanghui Zheng, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
Summer 2018. Clairice Dailey. Weil Institute of Emergency and Critical Care Research
Volunteer.
2017-2018. Mentor Jing Xu, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2017-2018 Mentor Chang-Sheng Wang, MD, PhD. Weil Institute of Emergency and
Critical Care Research Visiting Fellow.
2017-2018. Mentor Qinyue Guo, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2017-2018. Mentor Zhangle Hu, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
Summer 2017. Nikki Duggal. Weil Institute of Emergency and Critical Care Research
Volunteer.
2016-2017. Mentor Changqing Miao, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2016-2017. Mentor Jin Yang, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2016-2017. Mentor Tianfeng Hua, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2016-2017. Mentor Weiping Huang, MD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2016-2017. Mentor Yan Xiao, MD, PhD. Weil Institute of Emergency and Critical Care
Research Visiting Fellow.
2014-2017. Navami Ravindra BS Biomedical Engineering. Weil Institute of Emergency
and Critical Care Research and Department of Pediatrics Volunteer.
2014-2016. Mentor Tomohiro Akaba, MD, PhD. Department of Pediatrics Postdoctoral
Scholar.
2014-2016. Mentor Kosaku Komiya, MD, PhD. Department of Pediatrics Postdoctoral
Scholar.
2014-2016. Mentor Jonathan Ma, MD. Department of Pediatrics Pediatric Resident.
2014-2016. Mentor Ashleigh McCormick. Department Biomedical Engineering,
Undergraduate Researcher.
2013-2015. Mentor Isao Suzaki, MD, PhD. Department of Pediatrics Postdoctoral
Scholar.
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2013-2014. Mentor Shuichi Kawano MD, PhD. Department of Pediatrics Postdoctoral
Scholar.

Service
Graduate Student Rep, SOM Teaching Awards Selection Committee Summer 2020 and 2019
Volunteer Judge, Virginia Junior Sciences and Humanities Symposium (JSHS)
March 2020
Volunteer, Medical Reserve Corps
September 2008-Present
Volunteer, Emergency Department at MCV
Spring and Summer 2013
Mentor, Tutor of Education and Living Skills
August 2002-May 2006
Volunteer, Health Clinic in Ayacucho, Peru
Summer 2004
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